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Abstract
The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer
tumorigenesis and lung cancer stem cell maintenance
Brian Madajewski
Lung cancer is the leading cause of cancer related deaths worldwide. The five-year
survival rates for those patients suffering from non-small cell lung cancer (NSCLC),
continues to be an abysmal 15%. One of the major reasons for the poor survival rate
amongst NSCLC patients is the lack of early detection and subsequent late stage initial
diagnosis. Tumors discovered at later stages are often refractory toward chemotherapy
and radiation regimens. One theory as to why tumors become resistant to therapy relies
heavily on the cells that make up the cancer stem cell (CSC) niche. This small
percentage of cells within the heterogeneous tumor has been reported to be responsible
for drug resistance, tumor recurrence, and metastasis. In general, CSCs have been
isolated using a number of different markers, including cluster differentiation markers,
somatic stem cell markers, as well as a number of functional markers such as the side
population and aldehyde dehydrogenase (ALDH) activity. While some cancer types,
such as breast and hematologic cancers, have been significantly investigated to identify
and define their CSC population, lung cancer researchers have only recently begun to
identify CSC markers in lung tumors. In addition to the CSC population, malignant cells
can also alter their expression of a number of cytoprotective genes that promote
tumorigenesis. NAD(P)H:quinone oxidoreductase 1 (NQO1) is a detoxifying enzyme
that has been demonstrated to be highly overexpressed in a number of different
malignancies. This overexpression has been utilized as a drug target, as the enzyme is
expressed at low levels in normal tissue. To this point, there has been success in using
NQO1 as a drug target, however little research has been conducted on understanding
why NQO1 is overexpressed in these malignancies. The work presented here
investigated the role of NQO1 in tumorigenesis as well as its role in maintaining the
CSC population in NSCLC. We demonstrate that NQO1 promotes anchorageindependent growth, invasion, reactive oxygen species regulation, anoikis resistance,
proliferation, in vivo tumor growth, survival, and ALDH activity. Secondly, we
demonstrate that NQO1 also promotes spheroid formation, both in initial and serial
contexts, enhances the CSC frequency, and protects spheroid-cultured cells from
chemotherapy. Finally, we provide preliminary data that indicates that NQO1 mRNA
may be playing an important signaling role in the promotion of the CSC phenotype. This
was demonstrated by CRISPR-Cas9 genetic knockout of NQO1 that resulted in a
reemergence of the CSC phenotype that can be reversed with transient knockdown of
NQO1 mRNA. In summary, our data demonstrate that NQO1 is playing a vital role in the
promotion of NSCLC tumorigenesis, as well as supporting the cancer stem cell
population. Interestingly, these results may be due to a novel signaling mechanism by
NQO1 mRNA, and not the enzyme itself. Further research will be needed to completely
understand the role of NQO1 mRNA in NSCLC tumorigenesis and the CSC phenotype.
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Chapter 1
Introduction and Literature Review
Introduction
Lung cancer is the leading cause of cancer related death in the world (1). It is
predicted to be responsible for more than 158,000 deaths in the United States in the
year 2015 alone (2). In addition, the disease claims a greater number of lives than
breast, prostate, and colon cancer combined. Lung cancer is classified into two
histologically different categories, small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC). SCLC arises from a neuroendocrine origin, and occurs at a rate of
20% of all lung malignancies. These tumors are often more aggressive than their
NSCLC counterparts, resulting in 5-year survival rates of less than 5% versus 15% seen
in NSCLC (3, 4). The survival rates vary greatly depending on the stage at which the
cancer is detected, but often patients with SCLC present with advanced and
disseminated disease leading to an overall increase in mortality (5).
NSCLC is the most common type of lung cancer in the word, accounting for ~80% of
all lung cancer cases (6). NSCLC arises from the epithelial cell population within the
lung and can be further divided into three subcategories based on histological
assessment. Areas of keratinization and the presence of inflammatory components
define the first subtype of NSCLC, squamous cell carcinoma. Adenocarcinoma is
defined by the presence of glandular structures, or solid growths exhibiting mucin
production. This subtype also tends to be found in the periphery of the lung, where
squamous cell carcinoma typically originates near the bronchus. The histological
distinction of the third NSCLC subtype, large cell carcinoma, is decidedly more vague.
Cases lacking the defining features of squamous cell carcinoma or adenocarcinoma
tend to be classified as large cell carcinoma (7, 8). While it is possible to histologically
differentiate each tumor type, these distinctions provide little information on the
likelihood of recurrence, drug resistance, and metastatic capabilities of the cells.
Currently, it has become an area of great interest to determine the overall cellular
makeup of each tumor and define certain niches of cells that exist within, in order to
improve therapeutic approaches and patient outcomes.
Recently, the nearly 50-year-old hypothesis that cancer arises from a small
population of tumor initiating, or cancer stem cells (CSCs) has begun to once again
grab the attention of researchers (9). The belief is based on the premise of somatic
stem cells and their unique abilities. It is well known that somatic stem cells are crucial
for growth, differentiation, and repair of the normal tissues. They achieve these affects
by providing an unending supply of progenitor cells, while retaining the parental stem
cell population through asymmetric division (10). Adopting these traits, it is now believed
that cancers are capable of sustaining growth and promoting recurrence due to the
presence of a cancer stem cell (CSC) population. These cells harbor the ability to self-
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renew and give rise to progeny that are then able to differentiate into all cell types
necessary to constitute the complete makeup of a tumor.
Interestingly, it has also been demonstrated there exists an inherent plasticity in
transformed cells. Differentiated cancer cells possess the ability to return to their less
differentiated CSC phenotype as well revert back, thus indicating a divergence from
regulated somatic cell differentiation (11, 12). Nevertheless, this CSC population
appears to mediate resistance to therapy, making them difficult to eliminate (13-15).
This poses an obvious challenge in the treatment of cancer and in fact, therapies have
been shown to select for the more aggressive CSC phenotype, through the elimination
of the non-stem cell population (16-18). In addition to therapeutic resistance, the CSC
population has displayed enhanced capabilities in the processes of degradation,
invasion, and metastasis in comparison to their non-stem cell counterparts present
within a malignancy (14, 19, 20).
Due to CSCs abilities to reconstitute the entire heterogeneous makeup of a tumor,
their resistance to standard therapies, and demonstration of an increase in the ability to
metastasize to distant sites, a great amount of research has been directed at defining
this population in NSCLC. Elucidating this population will have great implications in both
the diagnostic and therapeutic aspects of cancer therapy. However, this approach is
made difficult by the elusiveness of the CSC population within the heterogeneous
population, since they can constitute as little as five percent of the total cell population.
This percentage however, can vary depending on the selection marker or method (21).
Currently, research is focused on a number characteristics thought to be correlative to
the CSC population, including specific cluster differentiation (CD) markers, efflux
pumps, detoxifying mechanisms, and stem cell signaling pathways. In order to
understand the importance of the
cancer stem cell population and its
implications
to
prognosis,
therapeutic resistance, recurrence,
and the future of drug design, it is
first necessary to understand the
concept of the cancer stem cell
hypothesis and those markers used
to define this elusive population.
The Cancer Stem Cell Hypothesis
The cancer stem cell hypothesis
originated more than 50 years ago,
and stated that a small subset of
cells within the overall tumor
population were responsible for the
initiation,
propagation,
and
maintenance of the neoplasm (22).
In order for this to be true, the CSC

Figure 1. Symmetric and asymmetric division of stem cells. Stem
cells (orange cells) are able to divide either asymmetrically into
progenitor cells (pale blue cells), or into another stem cell through
symmetric division. The symmetric divisions allow stem cells to
continually repopulate the stem cell pool, whereas asymmetric
division will give rise to progenitor cells. The progenitor cells then
begin to differentiate in multipotent, early progenitor cells (pink cells)
that will finally give rise to fully differentiated cell types (multi-colored
cells) that make up the respective tissue.
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population would need to display two characteristics that were already demonstrated by
the somatic stem cell population, 1) self-renewal and 2) the ability to give rise to
differentiated cell types (Figure 1) (9). By satisfying both of these requirements, CSCs
would be able to maintain the necessary stem cell population, as well as produce the
heterogeneous assortment of cells seen in malignancies.
The belief in CSCs was bolstered when Dick and colleagues were able to isolate a
CSC population within leukemia. Their work was the initial demonstration that a single
malignant cell could be administered in vivo and result in the onset of leukemia. The
induction of leukemia was capable of being carried out in serial experiments by isolating
the CSCs, and re-injecting that population into subsequent animals. The very first CSC
marker definition that they utilized was CD34+/CD38- (22).
Due to the impact of this finding, the cancer research community began to
investigate the possible presence of CSCs in all other forms of cancer. Since that time,
CSCs have been defined in multiple cancer types including breast, prostate, pancreas,
brain, ovary, and colorectal (23-28). However, this population has yet to be exhaustively
defined in NSCLC.
Lung Cancer Stem Cells
In the search for lung CSCs, researchers have developed a set of criteria in order to
delineate the stem cell population from that of the bulk tumor. The majority of these
characteristics have been adopted from the traits that normal, somatic stem cells
display. This approach has been utilized to define the CSC population throughout
numerous cancer types, and is being adopted similarly in lung cancer (10). The required
traits are commonly evaluated based on in vitro and in vivo assays, with the latter
approach providing the most definitive demonstration of a CSC. These approaches and
the traits they assess are briefly explained below.
In vitro Cancer Stem Cell Assays
There are a number of popular in vitro studies being utilized to demonstrate the
difference in the prominence of the CSC phenotype between various cell populations.
These techniques include sphere formation, soft agar colony formation, collagen
invasion, matrix degradation studies, and chemotherapeutic resistance assays (14, 2932). These assays demonstrate necessary characteristics of CSCs. Examples of this
include the ability to grow in an anchorage independent manner. The ability to grown in
the absence of a matrix is a hallmark of transformed cells. Spheroid formation and soft
agar colony formation are both assays designed to evaluate a cells ability to proliferate
in the absence of matrix attachment (33). Additionally, spheroid culture techniques
utilizing restricted media formulations are often implemented to specifically enhance
CSC populations. The reduction of differentiation-inducing factors allows for the
expansion of the undifferentiated CSC population (34, 35).
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The ability of malignant cells to degrade matrix and invade into the surrounding
tissue are two necessary processes of metastasis (36, 37). Interestingly the emergence
of metastatic disease is associated with increased mortality, where 90% of cancer
deaths are caused by metastases (38). The ability to establish metastatic disease has
been connected to the CSC population (19, 39). Migration and invasion capabilities are
often evaluated using a number of assays including wound healing, trans-well migration,
spheroid invasion, and organotypic cultures that more closely resemble the in vivo
environment (40, 41). Increases in these characteristics are often observed in the CSC
population in comparison to the non-CSC population, demonstrating a more invasive
phenotype (42).
Finally, examining the therapeutic resistance of a CSC population demonstrates the
inherent trait of being unaffected by cytotoxic therapy. Malignant cells that are resistant
to both chemotherapeutic and radiation treatments can lead to the recurrence of cancer
following significant reduction of the disease due to bulk tumor susceptibility to these
approaches (43). The resistance of CSCs to therapeutic approaches is so robust that
often CSCs are often selected for by treatment with chemotherapeutic drugs or radiation
(13). These results demonstrate the difficulty faced when trying to eliminate this
population, and demonstrate that treatments spare CSCs in comparison to the overall
tumor cell population (44).
In an effort to enhance the CSC population, and reduce the presence of non-CSCs,
these described techniques tend to utilize cells that are cultured as spheroids. The
ability to survive and expand in spheroid culture has been demonstrated to enhance the
stem cell signature in both cancer and normal cells (45, 46). Thus, it makes utilizing
spheroid culture an adequate method by which to expand the desired population for use
in subsequent experimentation.
In vivo Cancer Stem Cell Assays
A hallmark of a CSC population is increased tumorigenic propensity in comparison to
bulk tumor populations. Demonstration of increased tumor initiating capabilities can be
exhibited by injecting far fewer numbers of CSCs into immunocompromised animals, in
comparison to heterogeneous cell populations. The results demonstrate that injections
with reduced CSC numbers continually lead to tumor engraftment and growth that
resemble results observed with utilizing significantly greater numbers of non-CSC (47).
This is known as the in vivo limiting dilution assay, which continues to be held as the
gold standard demonstration of a CSC population. Tumors that arise can then be
assayed for resistance to therapy, invasiveness, and metastasis to sites such as the
lymph nodes, liver, bone, and brain. (48-51).
Self-renewal of the CSC population is also evaluated in vivo by performing serial
tumor forming assays in immunocompromised mice. Much like serial spheroid formation
assays in vitro evaluate a population’s ability to continually replenish the CSC
population, so do serial tumor forming assays (10). Continued tumor formation following
dissociation of primary tumors and injection into secondary recipients demonstrates the
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population’s ability to continually produce the tumor initiating, CSC population. Further
serial injections are often performed to validate the self-renewal capabilities of the
population in question (52).
The assays described above provide a functional validation of the CSC phenotype,
however they do not provide a suitable definition of the population of cells of interest. In
order to be able to effectively isolate and identify the CSC population it is commonplace
to select cells based on markers, often cluster of differentiation (CD) markers are
utilized. These markers are present on the surfaces of cells, and have been utilized to
isolate cell types depending on their specific CD marker expression (53). In the search
for CSCs, many investigators have coopted CD markers from other cancer types to
investigate their potential as a useful identifier of CSCs within their cancer of interest. In
addition to CD markers, the utilization of hyperactive signaling cascades can also be
utilized to define a CSC population.
Currently, NSCLC research is at the stage of utilizing known CSC markers from
other defined CSC populations like those found in breast, prostate, and glioblastoma in
an effort to isolate the NSCLC CSC population. Below, we review the most commonly
implemented markers and signaling pathways used in the attempt to define the NSCLC
stem cell population. (Figure 2) It should be noted that this field is currently in its infancy,
and there exist a large number of conflicting reports that make it very difficult to support
the utilization of many of these CSC markers in NSCLC.
Cluster Differentiation Markers

Figure 2. CD markers and cellular detoxification in non-small
cell lung cancer. Cancer stem cell populations are commonly
separated based on CD markers or detoxification pathways.
Common CD markers utilized in determining the non-small cell
lung cancer population include CD133 and CD44. CD133, a fivetransmembrane receptor, currently has no known function. CD44,
the hyaluronic acid receptor, has been utilized as a popular CSC
marker in a number of malignancies. ABC pumps are responsible
for the characterization of the side population. Cells that express
the ABC transporters are capable of extruding Hoechst dye, and
those cells with low dye retention are classified as the stem cell
population. Aldehyde dehydrogenase enzyme activity has been
utilized across many cancer types to define the CSC population.
Cells with high aldehyde dehydrogenase activity, as defined by the
Aldefluor Kit, have been demonstrated to have increased CSC
characteristics compared to those with low aldehyde
dehydrogenase activity.
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CD133
CD133, also known as Prominin 1,
is a five transmembrane glycoprotein
initially believed to be a hematopoietic
and neural stem cell marker in
humans (54, 55). It has since been
confirmed to be a hematopoietic stem
cell marker, and is utilized in the
screening of blood cells for allogenic
transplantation (56). CD133 has also
been employed to identify the stem
cell population within various types of
malignancies including colorectal,
brain, gastric, and NSCLC (57-60).
Cells that are determined to be
CD133+ within a tumor have been
reported
to
demonstrate
the
characteristics associated with CSCs
and function as prognostic indicators
(57, 61). While this CSC marker is
believed to be highly correlative to the

CSC phenotype, there are a number of conflicting reports concerning its association
with stemness. An example of this can be seen in the opposing findings produced by
Tirino and Meng et al (5, 62).
Tirino and colleagues have shown CD133 to be a strong marker of stemness,
selecting for cells with increased abilities to form spheres, increased levels of
anchorage-independent colony formation, and increased tumorigenic potential in vivo.
However, Meng and colleagues refute these findings by reporting that both CD133+ and
CD133- tumor cells are capable of forming spheres, as well as give rise to colonies in
soft agar experiments. Meng et al. also reported that CD133+ and CD133- cells were
both capable of in vivo tumorigenesis, and conveyed no discernable difference in their
invasiveness or resistance to chemotherapeutics.
While the studies referenced above demonstrate a difference in opinion, they are not
the only ones to do so. A large amount of literature can be found either for or against
the concept that CD133 expression can be utilized as a reliable marker to define the
CSC population within a tumor (57, 63, 64). Currently, it is clear that more research
must be done to determine if CD133 can be utilized as a definitive marker for CSC
within a heterogeneous tumor population.
CD44
CD44, like CD133 is an integral membrane glycoprotein expressed on the surface of
cells, and functions as the hyaluronic acid (HA) receptor (65). CD44 is most well known
for its role as a CSC marker in both breast and prostate cancers. CSC populations in
these tumors are defined as CD44+/CD24-/low, and it is this population that is said to
harbor the necessary traits to be defined as CSCs (23, 66). Currently, the usage of
CD44 in lung cancer is not well studied. However, in accordance with implementing
known CSC markers from other cancer types, researchers are beginning to explore the
possibility of utilizing CD44 as a NSCLC stem cell marker. In one study, Leung and
colleagues discovered that CD44+ NSCLC cells were enriched in stem cell properties,
but this finding was only applicable to their large cell carcinoma model. The stem cell
characteristics of CD44+ cells collected from an adenocarcinoma model failed to
demonstrate the increased tumorigenecity or drug resistance, seen in the LCC model
(67).
In agreement with the findings mentioned above, Wang et al. demonstrated that
CD44+ cells collected from NSCLC also had increased stem cell properties, however
this study also utilized the secondary marker, CD90, to further select the cell population
of interest. It was observed that upon collection of CD44+ cells, the properties displayed
by CSCs increased in this population. The phenotype was further enriched upon
secondary selection with CD90 (68). The subsequent CD44+/CD90+ classification calls
into question the value of CD44 as a standalone CSC marker in NSCLC. It is difficult to
say that the population collected by CD44 alone is the stem cell population due to CD90
increasing the CSC characteristics further. This study lacked the control of utilizing
CD90 alone as a CSC marker. Recently, CD90 has been shown to define the CSC
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population in esophageal cancer, further calling into question the applicability of CD44
as a CSC marker in tumors that have yet to have a defined CSC population (69).
Overall, CD44 has functioned extremely well as a CSC marker for both prostrate and
breast cancer. However, in NSCLC there is still little evidence to support the use of
CD44 as a CSC marker. Undoubtedly the completion of future work will elucidate
whether CD44 is a plausible option for selecting NSCLC stem cell populations.
Detoxification Pathways
Aldehyde Dehydrogenase (ALDH)
Aldehyde dehydrogenases are a family of enzymes responsible for detoxification,
drug resistance and cell differentiation. Their role in normal cellular metabolism is the
oxidation of harmful aldehydes into carboxylic acids, and the conversion of retinol into
retinoic acid (70, 71). Tumor cells that are positive for ALDH (ALDHhigh), and cells that
are negative (ALDHlow) are often selected utilizing the Aldefluor kit from Stem Cell
Technologies. This kit enables the labeling of cells with high levels of ALDH activity, and
allows sorting utilizing fluorescence assisted cell sorting (FACS) analysis.
In the lung epithelia, the expression and induction of isoforms ALDH1A1 and
ALDH3A1 have been thoroughly investigated. It has been shown that the expression of
both isoforms increase during malignant transformation of normal lung tissue (72, 73).
Other studies have also demonstrated an increased expression of ALDH1A1 and
ALDH3A1 in NSCLC cell lines (74). Interestingly, it was also observed that the
expression of ALDH is higher in the NSCLC than the expression detected in SCLC
leading to the possibility that ALDH expression may be a specific marker for NSCLC
CSCs (72).
These initial studies provided some support that the activity of ALDH isoforms may
be involved in NSCLC tumor initiation, progression, and stem cell maintenance. In
subsequent studies conducted by Sullivan and colleagues (75), it was found that
NSCLC cells that were found to be ALDH1A1+ had increased tumorigenicity,
clonogenicity, and self-renewal capabilities in comparison to ALDH1A1- controls. These
findings were further supported by the correlation of poor clinical outcome in patients
harboring ALDH+ tumors. Furthermore, this study demonstrated inhibition of the Notch
signaling pathway greatly decreased the levels of ALDH+ cells, as well as their CSC
characteristics.
In the Sullivan et al. studies discussed above, a controversial overlap between two
purported CSC markers is highlighted. It has been suggested that one CSC marker,
Notch, is responsible for the expression of another CSC marker, ALDH. In addition to
the overlap, this study also disputed the previously discussed CSC marker CD133. In
the manuscript by Sullivan and colleagues, CD133 did not correlate with poor patient
prognosis, indicating that it may not function as reliable prognostic tool. Additionally,
these results demonstrate that, in some instances, CSC markers believed to be
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perpetuating the CSC phenotype on their own may be working in conjunction with other
CSC markers.
Side Population
The side population of tumor cells, is defined as those cells that are capable of efflux
of the Hoechst 33342 dye (76). The ability of cells to have a high efflux capacity has
been demonstrated in cancer stem cell populations, thus it can be utilized as a marker
for the CSC population (77). Stem cells, and CSCs alike are able to efflux the dye
through an up regulation of the ATP-binding cassette (ABC) family of transporters (78).
These proteins lie within the membrane of cells and are responsible for the export of
endogenous entities, as well as the expulsion of cytotoxic compounds used to treat
malignancies (17).
It has been demonstrated repeatedly that the SP is capable of increased colony
formation, tumor sphere formation, invasion, and drug efflux (17, 20, 79-81). Taken
together, these characteristics provide a strong basis for characterizing these cells as a
CSC population. However, it has also been demonstrated that cells making up the nonSP population are capable of giving rise to a SP. Additionally, the SP was also able to
convert to other well-studied CSC such as CD133+ and ALDHhigh cells (82). Findings
such as this make it difficult to state whether a single marker is sufficient for defining the
CSC niche, or perhaps that these cells are able to transiently express certain markers
depending on cellular stage or state of tumor progression.
Signaling Pathways
Notch Signaling
The Notch family of transmembrane receptors plays a critical role in determination of
cell fate during development, as well as
in the maintenance of the somatic stem
cell population (83). Within the family,
there are four Notch receptors (Notch14) and five ligands (Delta-like-1, 3, 4
and Jagged-1, 2) (84). Unlike normal
receptor-ligand interactions the Notch
ligands are not in a soluble form, but
instead are present on neighboring cells
as single transmembrane proteins (85).
Notch signaling begins with the
binding of the Notch receptor to one of
its ligands. Following binding, the
extracellular domain of Notch is
dissociated from the transmembrane
domain and trans-endocytosed by the
cell expressing the ligand. Upon
removal of the extracellular domain,

Figure 3. Notch signaling pathway. Notch signaling occurs
between two neighboring cells where one expresses the Notch
receptor, while the other expresses one of the Notch ligands,
Delta or Jagged. Binding of the Notch receptor leads to a
proteolytic cleavage by the ADAM family of metalloproteases
and γ-secretase, releasing the notch intracellular domain
(NICD). Free NICD then translocates to the nucleus where it can
bind to the promoter of Notch effector genes such as Hes1 and
Hey1. The Notch downstream effectors then go on to effect
cellular differentiation and stemness.
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there are two proteolytic cleavages of the transmembrane domain, 1) by ADAM10 or
ADAM17 and 2) by γ-secretase. These two cleavage events release the Notch
intracellular domain (NICD) liberating it to translocate to the nucleus and act to alter
transcription (84) (Figure 3). There are a wide variety of transcriptional targets of the
NICD, including those pertaining to differentiation and stem cell maintenance (86).
Interestingly, it has also been shown that increased Notch signaling correlates with
increased activity of ALDH, as well as an observation that CD133+ cells have enhanced
Notch signaling (87, 88). The overlap of numerous stem cell promoting pathways
observed within the mentioned populations provides evidence that the CSC population
may rely on multiple mechanisms to sustain the population.
In addition to functioning as a possible regulator for ALDH+ and CD133+ cells, Notch
signaling has been demonstrated to impart a CSC phenotype in cells on its own. In
NSCLC, increased Notch signaling has been shown to enhance the CSC phenotype,
and correlates with poor patient prognosis in comparison to patients with low levels of
Notch signaling (89, 90). It has been observed that increases in Notch signaling
increase tumorigenicity, chemotherapeutic resistance, and radiation resistance (89, 91).
The combination of these qualities demonstrate that cells with increased Notch
signaling are more resistant to therapies than populations with reduced Notch activity
and therefore limit the efficacy of therapeutic intervention, leading to decreased survival
in clinic (92, 93).
Attempts to lessen the levels of Notch signaling have been attempted in NSCLC,
utilizing γ-secretase inhibitors (94). This approach hopes to lessen the numbers of CSC
within the cancer population, and thereby increase the ability of chemotherapeutics and
radiation to eradicate the non-CSC population and the overall tumor. Currently the use
of Notch inhibitors in the clinic has made it as far as Phase I clinical trial, and inevitably
more research will be done in order to advance the efficacy and safety of these drugs in
the future years (85).
Wnt Signaling
The Wnt pathway has long been known for its role in the regulation and maintenance
of normal stem cells, such as those found in the gut epithelium (95). It has also been
hypothesized that Wnt signaling can play a role in CSC regulation, where overactivation of this pathway can lead to the emergence of the CSC phenotype (96). Wnt
signaling is overviewed well by He et al, and will be briefly reviewed here (97). First,
Wnt signaling functions through at least three known pathways within cells (98). The
first, and best known, is the canonical pathway. Canonically, Wnt ligands bind to either
the Frizzled or low-density lipoprotein receptor-related receptors present on the
extracellular surface. This binding then activates Disheveled, a protein responsible for
the inactivation of glycogen synthase kinase (GSK). Inhibition of GSK inhibits the
phosphorylation of β-catenin, thereby stabilizing it. Stabilization of β-catenin allows for
its translocation to the nucleus where it is able to affect gene transcription (Figure 4).
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Other,
non-canonical
Wnt
signaling includes the planar cell
polarity and Wnt/Ca2+ pathways (98,
99). In addition the planar cell
polarity pathway has also been
demonstrated to lead to the
activation of the small GTPases
Rho, Rac, and Cdc42 (100-102).
Interestingly, the Rac family of
GTPases has also been implicated
in the maintenance of the CSC
population (79).
While the canonical Wnt/βcatenin pathway has been shown to Figure 4. Wnt Signaling Pathway.
play a crucial role in the The Wnt signaling pathway has been demonstrated to be important to
CSC population in a number of cancer types as well as in normal
maintenance
of
CSCs
in the
development. Under inactive conditions the Wnt effector protein, βmalignancies such as colon, liver, catenin (β-Cat), is sequestered by the destruction complex and
thus targeting it for ubiquitination and proteosomal
breast, and leukemia, its role in phosphorylated,
degradation. The destruction complex is composed of Axin, glycogen
NSCLS has yet to be clarified (103- synthase kinase 3 (GSK3), adenomatosis polyposis coli (APC) and
kinase 1 (CK1). During active signaling, Wnt ligand binds to
106). Teng and colleagues were casein
the LRP and Frizzled (Fz) receptors. Receptor activation causes the
able to demonstrate that the destruction complex to be recruited to the cytoplasmic tail of LRP by
phosphorylated Axin. Following relocation, Disheveled (DVL) is
canonical
Wnt
pathway
was now
activated, thus inhibiting the action of GSK3. Loss of GSK3 activity
responsible for the maintenance of leads to stabilization and accumulation of β-Cat within the cytosol.
β-Cat then translocates to the nucleus where it induces
the CSC phenotype within A549 Accumulated
the transcription of Wnt target genes.
cells by upregulation of OCT-4 and
increasing levels of cyclin D1. It was discovered that this effect was caused by a
decrease in the degradation of the basal level of β-catenin, hinting that the mechanism
of action may effect the phosphorylation of free β-catenin (96).
The normal functions of the Wnt pathway and its downstream effectors are known to
support and regulate the CSC population within tumors (107). Wnt signaling plays an
important role in certain cancer types, but is still understudied as a potential mechanism
of CSC maintenance in NSCLC. Future research will need to be conducted in order to
confirm the utility of the Wnt/β-catenin pathway as a marker for the CSC population
within NSCLC.
Summary of CD Markers and Signaling Pathways
Overall, the results from studies investigating CSC markers and pathways tend to
contradict one another in NSCLC. One study may find that a population positive for a
certain CD marker will display a CSC phenotype while the population without the CD
marker is still capable of demonstrating CSC characteristics in subsequent studies.
When investigation switches from CD markers to known somatic stem cell signaling
pathways, the results become clearer, however investigators often focus on upstream
regulators of known downstream stem cell promoting targets. An example of this would
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be Wnt signaling resulting in increased expression of the somatic stem cell marker Oct4 (96). These results cause us to wonder at which level of regulation is the effect being
perpetuated. Inhibiting upstream regulators of these stem cell pathways can have
numerous effects on all their downstream targets, therefore in order to create safe and
effective therapies, it is important to understand and target the effector molecules that
often lie further downstream.
Attempts to define the CSC population and target it have provided researchers new
angles by which to attack cancer, however it is not CSC markers and pathways that
have made up the bulk of drugs designed to target cancer. It is instead a myriad of
pathways and proteins that are overexpressed or overactive in malignancies. The belief
is that the reduction or inactivation of these pathways will result in decreased tumor
aggressiveness and better patient outcomes. Common oncogenic drivers such as
EGFR, K-Ras, and EML-ALK4 have all been shown to promote cancer initiation and
progression, as well as become major foci of targeted therapies (108-110). Targeted
therapy approaches often work well for a brief period of time, but over the course of a
number of months these tumors become refractory to these therapies and the next line
of therapy must be implemented. A great amount of research has been dedicated to
understanding why cancer becomes resistant to these approaches and aims to design
better drug formulations that may act in a more permanent fashion (111).
There also exists an interest in lesser-known, over-activated or over-expressed,
proteins observed in cancers. These can include proteins that are important to certain
cellular processes such as metabolism, cell motility, oxidative stress regulation, or
autophagy (112-115). One of these proteins, NAD(P)H:quinone oxidoreductase 1
(NQO1), has garnered a lot of attention recently as it is observed to be greatly overexpressed in a number of cancer types, including NSCLC, but expressed at very low
levels in normal tissues (116-118). This provides for an intriguing drug target as it can
be a cancer directed therapeutic thus reducing unwanted off target affects. The role of
NQO1 in cancer, and cancer therapy is discussed below.
NAD(P)H:quinone oxidoreductase 1
Overview
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a phase II detoxifying that takes part
in the obligate two electron reduction of harmful quinones, utilizing either NADH or
NAD(P)H as a cofactor. The quinones present within the cell can arise from exogenous
or endogenous sources including, estrogen derived quinones, dopamine derivatives,
and antitumor quinones (119-122). Unlike cytochrome p450 enzymes, this reduction
results in a stable hydroquinone that does not produce harmful reactive oxygen species
due to the presence of a free electron (123, 124). The stable hydroquinone formed by
NQO1 is later conjugated to glutathione and excreted from the cell. Interestingly, NQO1
has been demonstrated to be greatly overexpressed in a number of tumor types in
comparison to normal tissues (118, 125-127). These observations present researchers
with the possibility of being able to specifically target tumor cells utilizing NQO1 as a
drug target, thus sparing normal cells due to an inherent low expression of NQO1.
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NQO1-specific antitumor approaches are being investigated utilizing the orthonapthoquinone, β-lapachone (β-lap). Isolated from the lapacho tree, this compound has
been used medicinally for centuries and has recently garnered respect in cancer
therapy (128). β-lap’s mechanism of action is strictly dependent on the expression of
NQO1. NQO1 catalyzes the formation of an unstable hydroquinone form of β-lap that
spontaneously reverts back to the parent compound, thus resulting in the release of
reactive oxygen species. The level of reactive oxygen species released is extremely
high resulting in DNA damage, PARP1 hyper-activation, nucleotide depletion, and
eventual cell death (129). Promising pre-clinical results have supported β-lap’s
promotion to clinical trial. Known clinically as ARQ-501, or ARQ-761, β-lap has reached
stage II clinical trials in prostate cancer, as well as a currently enrolling stage I trial for
other solid malignancies (NCT01502800). In addition to stand-alone therapy with these
compounds, research is also being conducted to investigate the synergistic effects of βlap with radiation (130). It has been observed that ionizing radiation induces expression
of NQO1 leading to a synergistic effect when β-lap is administered following radiation
(131, 132). Despite the promise observed with β-lap treatment, caution must be taken
when attempting to treat patients with NQO1 directed therapy due to the presence of
polymorphisms.
Polymorphisms
Wild-type NQO1 protein is targetable via β-lap treatment, however two
polymorphisms of NQO1 exist. The *2 polymorphism, a cysteine to threonine
substitution at nucleotide position 609, results in a proline to serine substitution at
position 187 in the amino acid sequence (133, 134). The result of this polymorphism is a
highly unstable protein that has undetectable activity and is quickly degraded (135).
This form of the polymorphism is predicted to occur in 5-20% of patients (136).
Surprisingly, the presence of this polymorphism has been linked to the susceptibility of a
number of diseases including cancer, as well as often predicting worse outcomes (137143). These results counter what is observed in other reports where wild-type NQO1
expression leads to a worse overall survival, indicating a pro-tumorigenic role for NQO1
(117, 144-146). The *3 polymorphism exists due to a cysteine to threonine substitution
at nucleotide position 465 that results in an arginine to tryptophan substitution at amino
acid position 139 (147). This polymorphism results in an alternative splicing event that
renders substantially less protein in cells harboring the polymorphism (148). Studies
investigating the prevalence of these polymorphisms demonstrate that the *3
polymorphism occurs at a much lower rate (across different ethnic groups) than the *2
mutation (149).
Regulation
Expression of the NQO1 gene is controlled by a number of factors including
antiestrogens, electrophile response elements, and antioxidant response elements
(ARE) (150-152). The most commonly discussed is its regulation by transcription factors
binding to the ARE in the promoter region. The ARE consensus sequence,
TMAnnRTGAYnnnGCRwww, is capable of binding a number of bZIP transcription
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factors including Nrf1, Nrf2, Maf,
Jun, Fos, and Raf (153).
Additionally, it has been seen that
ERK signaling can result in the
increased expression of ARE
regulated genes (154).
The canonical regulation of
NQO1 is provided by the
transcription factor NF-E2-related
factor 2 (Nrf2) (153). Much like
NQO1, Nrf2 is also a commonly
studied protein in cancers as it too
has been observed to have an Figure 5. Nrf2 regulates the expression of NQO1 and other
stress regulating genes. The expression of NQO1 is under
increased expression in a number oxidative
the control of the Nrf2/Keap1 pathway. Under homeostatic conditions,
of cancer types (155, 156). Nrf2 Nrf2 is bound by Keap1 in a complex that includes the Cul3 ubiquitin
Under these steady state conditions Cul3 is capable of
exists in equilibrium with its ligase.
polyubiquitinating (grey circles) Nrf2, thus targeting it for proteosomal
negative regulator Kelch-like ECH- degradation. Under conditions of oxidative stress, Keap1 acts as a
that then releases Nrf2. The free Nrf2 is then capable of
associated protein 1 (Keap1). sensor
translocating to the nucleus and binding to antioxidant response
Keap1 binds to Nrf2 and elements (ARE), along with other co-activators (Maf pictured) of
sequesters it in the cytoplasm, oxidative stress regulating genes, including NQO1.
restricting the transcription factor
from interacting with the DNA and inducing transcription. The binding of Keap1 to Nrf2
allows for the Cullin 3 (Cul3)-based E3 ubiquitin ligase to associate with the complex,
inducing the poly-ubiquitination of Nrf2 and subsequent proteosomal degradation (157).
Under periods of oxidative stress, the Nrf2/Keap1 association is lost due to the oxidation
of cysteine residues on Keap1 (158). Loss of association allows for Nrf2 accumulation
and relocation to the nucleus. Upon localization to the nucleus, Nrf2 can bind to the
AREs of its canonical targets and induce their expression (159). In addition, roughly
15% of lung cancer patients harbor Keap1 mutations that inhibit the interaction of Keap1
with Nrf2 that leads to increased activity of Nrf2 (156) (Figure 5).
Interestingly, Nrf2 has recently been demonstrated to regulate the expression of
Notch and control the division and proliferation of normal bronchial stem cells (160). The
report directly connects oxidative stress regulation to the maintenance of stem cell
populations, and suggests that this may also be the case in the cancer stem cell
population. Of note, it has also been demonstrated that increased Notch activity results
in an increase in Nrf2 expression in liver cancer (161). These observations suggest that
there is a reciprocal regulation of these two proteins by one another (162).
Summary
Research into the role that NQO1 plays in promotion of tumorigenesis and why it
tends to be overexpressed in a number of malignancies is essentially non-existent. The
majority of research focus on tumor promotion is focused on the canonical NQO1
regulator, Nrf2 and its tumor supportive role (163, 164). Given that there is little work
focused on understanding the role of NQO1 in tumorigenesis, it comes as no surprise
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that the importance of this oxidative stress regulator, in the CSC population, has also
not been evaluated. Here we present work that demonstrates NQO1 plays a vital role in
NSCLC initiation and progression, as well as being imperative in the maintenance of the
CSC population in NSCLC. These results provide novel insight into the greater
involvement of NQO1 in the promotion and progression of NSCLC, beyond its simple
overexpression
and
usefulness
as
a
drug
target.
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Abstract
The fundamental role that NAD(P)H/quinone oxidoreductase 1 (NQO1) plays, in
normal cells, as a cyto-protective enzyme guarding against stress induced by reactive
oxygen species (ROS) is well documented. However, what is not known is whether the
observed overexpression of NQO1 in neoplastic cells contributes to their survival. The
current study discovered that depleting NQO1 expression in A549 and H292 lung
adenocarcinoma cells caused an increase in ROS formation, inhibited anchorageindependent growth, increased anoikis sensitization and decreased 3-D tumor-spheroid
invasion. These in vivo data further implicate tumor-NQO1 expression in a pro-tumor
survival role, since its depletion suppressed cell proliferation and decreased lung tumor
xenograft growth. Finally, these data reveal an exploitable link between tumor-NQO1
expression and the survival of lung tumors since NQO1 depletion significantly
decreased the percentage of ALDH(high) cancer cells within the tumor population.

16

Introduction
Lung cancer is the leading cause of cancer related deaths in the U.S. (2). Over the
past decade some improvement has been made toward the goal of increasing overall
survival in lung cancer patients. These improvements have mostly been due to
technological advances allowing early diagnosis of lung cancer as well as improved
molecular based therapeutic approaches (165). However, with 5-year survival rates at
15% or less, novel mechanism based therapeutic approaches are still desperately
needed.
NADPH quinone oxidoreductase-1 (NQO1) is an inducible two-electron
oxidoreductase that is highly overexpressed in many solid tumors including breast,
pancreas and non-small cell lung cancer (NSCLC) (116, 118, 166-171). NQO1 is an
essential phase II detoxification gene and as such plays a critical role in both
detoxification and bio-activation of many DNA damaging quinones (167). As a chemopreventive gene, NQO1 has been shown to detoxify a broad spectrum of quinone
substrates and it plays a role in reactive oxygen species (ROS) scavenging by
generating antioxidant forms of alpha tocopherol (167, 172).
In our past investigations we demonstrated that NQO1 bioactivated several
anticancer quinones including b-lapachone (173) and more recently deoxynyboquinone
(DNQ) (174). Our previous in vitro studies determined that NQO1 is a viable target for
developing personalized lung cancer therapy since tumor-NQO1 levels are often 5-20
fold greater in lung tumors as compared to the levels of NQO1 observed in associated
normal tissues (170). Thus, targeting NQO1 with anticancer quinones has become a
feasible option for preclinical anticancer studies. Furthermore, our in vivo studies with
anticancer quinones and novel drug delivery formulations, has led to a surge in interest
in NQO1-bioactivated anticancer quinones (174, 175), resulting in clinical trials for
treatment of various solid tumors. However, there is still very little known as to why
NQO1 levels are so vastly overexpressed in solid tumors. More specifically, no studies
have addressed whether reducing tumor-NQO1 levels affects processes critical to
tumor survival and proliferation, including anchorage-independent growth, escape from
apoptosis and the ability to invade and metastasize.
In the current study we hypothesized that depleting NQO1 expression levels in
NSCLC tumors would have deleterious effects on cell proliferation and survival. Our
rationale for this hypothesis stemmed from numerous reports suggesting that cancer
cells must regulate oxidative stress levels to prevent death from toxic levels of ROS
created in their microenvironment as part of a host defense response (176). Thus, one
strategy to protect tumor cells from lethal levels of ROS stress is to activate, or hijack,
pathways that regulate the expression levels of antioxidant genes. Importantly, a
primary regulator of oxidative stress is the transcription factor Nrf2 whose role is to
activate antioxidant gene expression; and its own overexpression has been associated
with enhanced tumorigenesis (163, 177, 178). One of the many transcriptionally
activated antioxidant genes regulated by Nrf2 is NQO1, and numerous studies have
shown that NQO1 levels in various tumors are elevated in comparison to associated

17

normal tissues (116, 118, 170). Here we show that depletion of NQO1 expression
levels, in various NSCLC cell lines, decreased the tumor cells ability to form colonies in
anchorage-independent growth assays. The inability of NQO1-depleted NSCLC cells to
form tumor colonies in anchorage-independent assays correlated with increased
reactive oxygen species formation, an increase in anoikis sensitization and a decrease
in cell proliferation rates. Our data also show that depletion of NQO1 expression levels
inhibited the ability of NSCLC cells to invade in 3D-tumor spheroid assays. Our in vivo
data show that loss of tumor-NQO1 expression in NSCLC cells inhibited tumor growth
as compared to controls. Finally, we show that NQO1 knockdown decreases the
percentage of ALDH(high) cancer cells, suggesting that the depletion of NQO1 decreases
tumorigenicity by eliminating the cancer stem cell population within the tumor. Together
these novel findings illuminate the role of NQO1 in tumors, and suggest that depleting
tumor-NQO1 levels disrupts the protective barrier against ROS provided to cancer cells
by elevated tumor-NQO1 expression levels. Thus, NQO1 depleted tumor cells are more
susceptible to oxidative stress and their overall growth and survival is inhibited due to
increased cell death, and reduced proliferation of the cancer stem cell population.
Materials and Methods
Reagents
NQO1 activity assay kit (Abcam), Cell death detection ELISA kit (Roche Applied
Sciences), Seaplaque agarose, SeaKem agarose, 1N Sodium Hydroxide and Rat tail
collagen type I (Fisher Scientific), Noble agar (Becton, Dickinson), 10X DPBS
(Hyclone), Cyquant cell proliferation assay kit and 2', 7'-dichlorodihydrofluorescein
diacetate, acetyl ester, DCFDA (Lifetechnologies). The NQO1 inhibitor Mac220 was a
generous gift from Dr. David Ross, University of Colorado Anschutz Medical Center.
Cell growth and maintenance assays
H292, HCC1171 and non-transformed, non-tumorigenic human bronchial epithelial
(HBEC) cell lines were a generous gift from the laboratory of Dr. John D. Minna, UTSW
Medical Center at Dallas. A549 and H596 cells were previously described (170). A549,
H596, H292 and HCC1171 cell lines were cultured in DMEM (Lonza) containing 10%
fetal bovine serum (FBS) and 1% L-glutamine. HBEC cells were cultured in
Keratinocyte Serum-Free Media with supplements (Invitrogen). All cell lines were
incubated at 37°C at 10% CO2.
Western Blotting
Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room
temperature, and then incubated overnight with β-actin (1:5000 in 3% BSA, Santa Cruz
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa
Cruz Biotechnology). Pierce ECL western blotting substrate (Thermo Scientific) was
used to visual bands on Hyblot-CL autoradiography film (Denville Scientific). For
PARP-1 cleavage assays, A549 (shCtr-R and shNQO1) tumors were harvested post
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mortem and sonicated in PARP-lysis buffer as described previously (173, 179). Extracts
were resolved in 10% SDS-PAGE gels and transferred to a PVDF membrane. PARP-1
protein was visualized using a monoclonal PARP-1 antibody (Santa-Cruz, clone F-2) at
a 1:1000 dilution.
Patient survival analysis
Three separate survival analyses were performed on overall survival data from
NSCLC patients obtained from 3 TCGA data sets (https://tcga-data.nci.nih.gov/tcga/)
(180-182). Gene expression values used were reported from Affymetrix U133A
Microarray data. Patient data with valid gene expression levels were used to estimate
medians and bounds for upper and lower quartiles. Patients were categorized into two
groups based on whether the values of gene expression were above the upper quartile
bound and below the lower quartile bound. Kaplan–Meier survival graphs were plotted,
and log-rank tests were performed using GraphPad Prism.
Transient and stable NQO1 protein knockdown assays
The human shRNA-NQO1 retroviral vector (RHS1764-9691437) was purchased
from Open Biosystems. A stable shRNA knockdown cell line (A549-shNQO1) and
vector control (A549-shCtr-R) was generated by infecting A549 cells with polybrenesupplemented medium obtained from Phoenix packaging cells transfected with the
human retrovirus vector targeting NQO1 or non-silencing control vector as described
previously (168). Human shRNA-NQO1 lentiviral particles (sc-37139) and controls were
purchased from Santa Cruz Biotechnology. Stable shNQO1 lentiviral knockdown (A549shNQO1-B) and control (A549-shCtr-L) lines were generated by infecting A549 cells
with polybrene-containing culture medium (5 µg/mL) and 10 µL of the lentiviral particles
were added directly to the culture medium. Medium was changed 24 hours after
transfection. After 48 hours shNQO1 containing cells were isolated by limited dilution in
media containing puromycin (2 µg/mL) and screened for NQO1 expression levels by
Western blot. Similar experiments were performed with H292 cell lines to create H292shNQO1-B and H292-shCtr-L cell lines. H596 cells, which are NQO1 null, were infected
with retrovirus particles from a retroviral control (LPC-X) or retroviral NQO1 (LPCNQO1) vector as described previously (9). For transient NQO1 knockdown, siRNANQO1 or scramble control siRNA (Santa Cruz Biotechnology) was transiently
transfected into HCC1171 or H596 cell lines (Lipofectamine 2000, Life Technologies)
using the Life Technologies protocol. Cells were harvested after 48 hours and analyzed
for NQO1 protein expression or enumerated using a hemocytometer for use in invasion
assays.
NQO1 activity assays
To analyze endogenous NQO1 levels we used an NQO1 activity assay kit (Abcam).
Briefly, cell pellets, containing 2X107 cells, were collected for each cell line. Pellets were
solubilized in 1X extraction buffer on ice for 20 minutes. Samples were then centrifuged
at 18,000 x g for 20 minutes at 4°C. Supernatants were transferred to new eppendorf
tubes and aliquots were stored at -80°C. Protein concentration was determined using
the Bio-Rad protein assay method. Samples were diluted to 2X the working
concentration of 5 µg/mL with supplemented buffer. Two wells were prepared for each
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sample (one well with and one well without inhibitor). 50 µL of each cell line was plated
in triplicate in 96 well plates provided with the kit. The reaction buffer and the reaction
buffer plus inhibitor were prepared according to the manufacturer’s calculation table.
The reaction buffer plus inhibitor were added to the samples first. Reaction buffer
without the inhibitor were added last. Absorbance was measured at 440 nm every 20
seconds for 5 minutes using the Synergy-H1 Hybrid microplate reader. The plates were
shaken before and after each reading.
In vitro survival assays
Long-term survival assays based on DNA content after 7-10 days of growth were
conducted in 48 well dishes as previously described (170, 173). Cells were treated with
vary doses of ARQ-761 (aka b-Lapachone) in the presence or absence of the NQO1
inhibitors dicoumarol or 5 µM Mac 220.
Cell Proliferation Assays
To determine cell proliferation rates we used the CyQUANT cell proliferation assay
kit (Life Technologies) and followed the manufacturers protocol. Briefly, standard curves
were generated by pelleting 1X106 cells for all cell lines. Pellets were resuspended in 1
mL of CyQUANT GR/cell-lysis buffer and vortexed briefly. A dilution series in one row of
a 96 well microplate ranging from 50 to 50,000 cells per cell line in total volumes of 200
µL were plated along with a 200 µL control well with no cells and incubated for 5
minutes in the dark at room temperature. Using a Synergy-H1 Hybrid Reader (Bio Tek),
fluorescence was measured at excitation 480nm and at 520nm emission. For
proliferation, cells were plated out in 6 wells at 5,000 cells per well in a total of 200 µL of
a 96 well plate. Multiple plates were seeded using the same starting concentration and
cultured at 37°C and 10% CO2 until desired time to collect the plates. Plates were
collected at 0, 24, 48, and 72 hours by inverting the plates and blotting on a paper towel
to remove medium from the wells. Plates were stored at -80°C until all plates were
collected. Plates were thawed at room temperature and 200 µL of CyQUANT GR/celllysis buffer was added. Plates were incubated for 5 minutes in the dark at room
temperature.
Anchorage-independent growth assays
For A549 cell lines, a 1.5% SeaPlaque Agarose (SPA) mixture was made by slowly
adding SPA to PBS and autoclaving. 0.5% SPA was created by diluting the 1.5% stock
SPA 1:3 with culture media. 1 mL of the 0.5% SPA mixture was added to each well of a
6 well plate to create a bottom layer and allowed to solidify at room temperature for 1520 minutes. Cells were counted and suspended at 750 cells/mL in a separate 0.5% SPA
mixture. 2 mL were added to each well on top of the bottom layer and allowed to solidify
for 30-45 minutes at room temperature to create a cell layer. A 0.3% SPA mixture was
created by diluting the 1.5 % stock SPA 1:5 with culture media. 1 mL of the 0.3% SPA
mixture was added to each cell layer and allowed to solidify for 20-30 minutes at room
temperature to create a top layer. 250-500 µL of culture media was added onto the top
layer to prevent from drying out. A similar method was used where SeaKem Agarose
was substituted for SeaPlaque Agarose yielding similar results. Plates were wrapped in
parafilm and placed at 37°C. 250-500 µL of new culture media was added every week.
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Plates were imaged after 3 weeks (A549 cells) and 6 weeks (H292 cells) using and
Epson V700 photo scanner. The enumeration of colonies present in each dish was
quantified using imageJ software.
Cell Death Elisa (CDE, anoikis) assays
A cell death detection ELISA kit was used to determine the level of detachment
induced cell death (anoikis). Briefly, cells were seeded at a density of 250,000 cells in a
10cm dish for 48 hours prior to plating for assay. 2.0 mL of 0.5% methylcellulose and
culture medium mixture was added to poly-HEMA coated plates and allowed to
equilibrate in the incubator for 1 hour at 37°C. 150,000 cells were seeded per well in the
0.5% methylcellulose mixture and incubated at 37°C for the 24 and 48 hour time points.
For the zero hour time point cells were placed directly into Eppendorf tubes and placed
on ice. Cells were lysed with 100 µL of CDE lysis buffer at 4°C for 20 minutes. Cells
were pelleted for 12 minutes at 4°C at 13,000 rpm. 75 µL of the supernatant was
transferred to a new tube and stored at -80°C until all time points were collected. All
samples were processed using the cell death detection ELISA kit with the manufactures
protocol. Absorbance values were recorded using the Synergy-H1 Hybrid reader (Bio
Tek) at 405 nm. Values were calculated by subtracting the zero hour time point from the
24 and 48 hours time points.
Invasion assays
Invasion assays were performed as described previously (183). Briefly a 1.5% noble
agar/ PBS mixture was made and then autoclaved. Using a multi-channel pipette, 100
µL of the noble agar mixture was added to each well of a 96 well plate. Cells were
counted and suspended at a density of 50,000 cells/mL. 200 µL of this suspension was
added to the 96 well plates once the noble agar was solidified. Plates were allowed to
sit for 1-3 days depending on cell line until spheroids were formed. Once spheroids
were formed, a 400 µL base layer mixture of 10X DPBS, 1N sodium hydroxide, sterile
water and rat tail collagen was added to a 24 well plate and allowed to solidify at 37°C
for 30 minutes. Using a nucleofector pipette, spheroids were added one at a time to
Eppendorf tubes. 3 spheroids were added to each tube. Spheroids were centrifuged at
1,000 rpm for 3 minutes. The media was removed from each tube using a nucleofector
pipette. A collagen cell layer mixture was made and 500 µL were carefully added to
each tube, one at a time, and spheroids were added to the 24 well plates. The cell layer
was incubated at 37°C for 1 hour. 1 mL of culture media was added to the top of the cell
layer to prevent the collagen from drying out. Once media was added, zero hour images
were taken at 5X (A549 and HCC1171 cells) or 10X (H292) magnification using an
inverted microscope (Axiovert 200M, Zeiss). Images were taken every 24 hours until
invasion distance was outside of the focal field of view. The scale bar in each image
represents 100 microns. Using the AxioVision software, the invasion distance was
calculated by subtracting the initial spheroid radius from the invasive distance at the
final time point.
DCFDA staining for ROS studies
500,000 cells were plated in 10 cm dishes containing 7 mL of 0.5% Methylcellulose
mixture. Cells were incubated for 24 hours at 37°C and 10% CO2. After 24 hours pellets
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were collect by centrifuging at 1,000 rpm for 2 minutes. Pellets were washed 1X with
PBS and centrifuged at 1,000 rpm for 2 minutes. Pellets were resuspended in DMEM/F12 without phenol red, which contained either 5µM DCFDA (stained) or DMSO
(unstained control), and transferred to flow cytometry tubes. Cells were incubated at
37°C and 10% CO2 for 30 minutes. Cells were then pelleted again at 1,000 rpm for 2
minutes. Pellets were resuspended in 500 µL of DMEM/F-12 without phenol red and
placed at 37°C and 10% CO2 for 15 minutes to equilibrate and then samples were read
using the LSR Fortessa (BD Biosciences).
In vivo tumorigenesis and survival assays
For tumorigenesis assays 4-6 week old female athymic nude mice (Charles River)
were subcutaneously injected on the right flank with A549 shCtr-R and A549 shNQO1
cells on the left flank. Mice were stratified into 3 groups containing initial tumor injection
concentrations of 5 million, 2.5 million or 1 million cells of each cell type. 10 mice were
used for each group. Tumor growth rates were monitored by caliper measurements
using the formula (L x W2/2). Statistical significance between A549-shNQO1 and A549shCtr-R tumor growth rates, at each concentration, was calculated using an unpaired,
two tailed Students t-test.
In separate studies, to compare the effect that NQO1 depletion had on overall
survival, 4-6 week old athymic female nude mice (Charles River) were subcutaneously
injected with A549-shCtr-R or A549-shNQO1 cells into their flanks. Tumor growth rates
were monitored by caliper measurements using the formula (L x W2/2). Tumor growth
was assessed until the tumors reached the set volume of 1000 mm3. Post mortem,
tumors were collected for evaluation of NQO1 expression. Log-rank test were applied to
survival analyses (Kaplan-Meir). All statistical significance assessments were conducted
using Graph-Pad Prism 6 software.
All animal studies were performed in accordance with the animal care policies of
West Virginia University and were approved by the West Virginia Animal Care and Use
Committee.
Aldefluor activity assays
The percentage of cells that were ALDH(high) within the various cell populations assayed
was determined using the Aldefluor Kit (Stemcell Technologies). The kit was used
according to the manufactures protocol. Briefly, two flow cytometry tubes, per cell line,
were labeled as control or test. Cells were trypsinized and pelleted at 1,000 rpm for 1-2
minutes. 1 X 106 cells were then counted out for both shCtr-R and shNQO1 cell lines.
Pellets were washed 1X with PBS and resuspended in 1mL of the Aldefluor Assay
Buffer provided and transferred to the “test” tube. 5µL of the DEAB (ALDH inhibitor) was
added to the “control” tube and was immediately recapped. 5µL of the Aldefluor reagent
was added to the “test” tube and was vortexed immediately. After the “test” tube had
been vortexed, 500µL of the Aldefluor Assay Buffer was transferred from the “test” tube
to the “control” tube and the “control” tube was immediately vortexed. That procedure
was repeated for each cell line. Once all cells line were stained, the “test” and “control”
tubes were incubated at 37°C for 30 minutes. After the incubation period, tubes were
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centrifuged at 250 rpm for 5 minutes. Supernatant was removed and pellets were
resuspended in 500µL of Aldefluor Assay Buffer and samples were placed on ice. A549
samples were assessed using a Fortessa flow cytometer and Mia PaCa and PC3 cell
lines were analyzed using a Facs Calibur flow cytometer (Becton Dickinson). Final data
analysis was performed using FCS Express software.
Cell viability assays
HBECs were transiently transfected with siRNA-NQO1 or scramble control according
to the protocol described above. After the 48 h transfection period, cells were
enumerated and seeded at a density of 20,000 cells/ well in 96 well plates (white). The
following day, the viability of cells in each group (8 wells/ group was assessed by adding
100 µL of CellTiter-Glo (promega) to each well. Luminescence was detected using a
Synergy-H1 Hybrid reader (Bio Tek).
Statistical analysis
Statistical differences were determined by using Student's t tests, and p values were
reported. All statistical analyses were
performed using Graph-Pad Prism 6
software, and considered significant
when p values were < 0.05.
Results
Elevated NQO1 expression predicts
poor survival in NSCLC patients.
In previous studies our laboratory,
as well as other investigators, reported
that NQO1 expression levels were
highly elevated in lung cancer patient
tumor versus associated normal lung
tissue (170, 184). Elevated tumorNQO1 levels have provided a distinct
advantage for developing NQO1directed anticancer therapeutics such
as b-lapachone and deoxyniboquinone
(174, 175). However, in more recent
retrospective investigations of patient
outcomes,
a
strong
correlation
between
elevated
tumor-NQO1
expression levels and poor patient
survival in various cancer types
including breast and ovarian cancers
has emerged (185, 186). Thus, we
sought to determine whether elevated
NQO1 expression in lung tumors also
confers a survival disadvantage in lung

Figure 1. Elevated NQO1 levels in NSCLC patient tumors
decreases their overall survival. In A, Kaplan-Meier analysis of
patient survival based on tumor NQO1 expression levels from a
TCGA data set. Patients were grouped into NQO1 low and NQO1
high expression groups as described in “Materials and Methods”.
In B, Western blot analysis of A549 and H292 cells stably
transduced with retroviral (shNQO1) or lentiviral (shNQO1-B)
NQO1 constructs. In C and D, A549 and H292 NQO1 knockdown
cell models from (B) were assayed for NQO1 enzyme activity, and
activity was expressed as nMoles/min/µg of protein. In C, p values
for A549 shCtr-R vs A549 shNQO1 (p <0.0001) and for A549
shCtr-L vs A549 shNQO1-B. (p = 0.0002) In D, p values for H292
shCtr-L vs shNQO1-B (p = 0.0114).
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cancer patients. We analyzed gene expression and survival data from NSCLC (lung
adeno- and squamous cell carcinoma) patients within The Cancer Genome Atlas
(TCGA) (180-182). Patients were stratified into high and low NQO1 expressers based
on a quartile bound cutoff. With this cutoff, a total of 191 patients were identified as high
expressers and 244 patients were identified as low expressers. Our data, in three
separate analyses, show that lung cancer patients with high tumor-NQO1 expression
levels have worse overall survival (Figure 1A and Supplemental Figure 1). Our data
are consistent with the aforementioned reports of poor overall survival in breast and
ovarian cancer patients whose tumors had high NQO1 expression levels (185, 186).
These data, as well as our laboratory observations that NQO1 levels increase during
the process of transformation, suggested that cancer cells increase NQO1 expression
levels as part of a pro-survival strategy during tumorigenesis, and that depleting NQO1
levels could possibly eliminate this survival advantage.
Depleting tumor-NQO1 levels inhibits anchorage-independent growth and
invasion of NSCLC.
To investigate whether depleting NQO1 would alter the growth of lung cancer cells
we used NQO1 shRNAs to establish stable
knockdown of NQO1 in A549 and H292
NSCLC cell lines. Our data show that
shNQO1 knockdown in A549 cell lines
using a retroviral vector (shNQO1) or
lentiviral vector (shNQO1-B) caused a
significant decrease in NQO1 protein
expression levels (Figure 1B and
Supplemental
Figure
2A),
which
correlated with loss of NQO1 activity
(Figure 1C). Similar results are shown for
NQO1 knockdown in H292 cells (Figures
1B lower panel and 1D). The parental
A549 cells have nearly 12 fold higher levels
of NQO1 activity as compared to the levels
of NQO1 activity detected in H292 cells.
Thus, these two cell lines with their distinct
differences in NQO1 activity levels, also
serve as an internal comparison to
determine whether patients with lower
NQO1 levels in their tumors could also
benefit from therapeutic strategies aimed at Figure 2. Depleting NQO1 expression levels inhibits
growth of NSCLC cells in soft agar. In A, A549 shCtr-R
depleting NQO1 expression.
and A549 shNQO1 cells were analyzed for their ability to
A hallmark of oncogenic transformation
is the newly acquired ability of a
transformed cell to grow in an anchorageindependent environment. This acquired
phenotype also increases the invasive and
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form colonies and grow in soft agar. Photomicrographs
shown are representative of experiments performed in
sextuplet. In B- D, graphical representation of enumerated
colonies for A549 shNQO1, A549 shNQO1-B and H292
shNQO1-B cells versus A549 shCtr-R, A549 shCtr-L and
H292 shCtr-L cells. In B, p values for A549 shNQO1 vs
A549 shCtr-R (p (<0.0001). In C, p values for A549
shNQO1-B vs A549 shCtr-L (p = 0.0041). In D, p values for
H292 shNQO1-B vs H292 shCtr-L (p=0.0114).

metastatic potential of transformed cells. In previous reports A549 and H292 cell lines
served as metastatic models for in vivo studies (187, 188). Thus, we hypothesized that
stable shRNA knockdown of NQO1 in A549 and H292 cells would be sufficient to
determine whether NQO1 depletion affected tumor growth in anchorage-independent
colony forming assays (also referred to as soft agar assays). In Figures 2A-D and
Supplemental Figure 3 our data show that stable depletion of NQO1 significantly
inhibits the growth of A549 and H292 cells in soft agar assays. Interestingly, the
inhibition of NQO1 expression in A549 cells using the shNQO1 vector was substantially
greater than what was observed with
the shNQO1-B vector. Thus, the higher
NQO1 activity observed in shNQO1-B
A549 knockdown cells (Figure 1 C)
correlated with more colony growth
(Figure 2C and Supplemental Figure
2B). These data suggest that the
degree of NQO1 activity loss affects the
ability of cells to grow in soft agar. In
addition to NQO1 shRNA knockdown
studies we examined the effect of
dicoumarol and Mac 220, NQO1
inhibitors that mimic the co-factor
NAD(P)H which is required for NQO1
activity (189), on colony growth. Our
data show that the NQO1 inhibitors
dicoumarol
and
Mac220
also
significantly inhibited the growth of
A549 cells in soft agar colony forming
assays (Supplemental Figures 4 and
5), further confirming that anchorageindependent growth in these cells is
Figure 3. Loss of NQO1 expression inhibits invasion of
affected by the loss of NQO1 activity.
NSCLC. In A, and C, 3D- tumor-spheroid invasion assays were
performed on A549 shNQO1, H292 shNQO1-B and A549 and
H292 shCtr-L cell lines as described in “Materials and Methods”.
Shown are photomicrographs of representative spheroids from
each cell line at 0 and 72 (h). In B and D, graphical presentation
of the tumor-spheroid invasion distance migrated by A549
shNQO1 and H292 shNQO1-B cells as compared to A549 and
H292 shCtr-L cell lines. In B, p values for A549 shNQO1 vs
A549 shCtr-R (p<0.0001). In D, p values for H292 shNQO1 vs
H292 shCtr-L (p<0.0001)

To further confirm the role of NQO1
in anchorage-independent growth we
examined the effect of NQO1
overexpression in H596 cells, which are
NQO1 null due to the *2 polymorphism.
Our
data
show
that
NQO1
overexpression in H596 cells (H596-LPC-NQO1) caused significantly more colony
growth as compared to vector only H596-LPCX cells (Supplemental Figure 6). In
contrast, our data show that transient knock down of NQO1 in H596-LPC-NQO1 cells
results in significant loss in their ability to grow in soft agar (Supplemental Figure 7).
These data further indicate that NQO1 plays a role in the survival of cells in an
anchorage-independent environment.
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The ability to survive in an anchorage-independent environment is uniquely tethered
to a cancer cells ability to invade and metastasize (190). Thus, we employed an in vitro
3- dimensional spheroid invasion assay (183, 191) to address the role that NQO1 plays
in the process of tumor cell invasion. Our data show that stable knock down of NQO1 in
A549 cells decreased the overall area of lung tumor spheroids (Supplemental Figure
8A) and inhibited the invasive progression of lung tumor spheroids in A549 and H292
cells (Figures 3 A-D and Supplemental Figure 8B). In addition to A549 and H292
cells, our data show that transient
depletion of NQO1 expression using
siRNA also inhibited invasion in
HCC1171
lung
cancer
cells
(Supplemental Figure 9). In
contrast to NQO1 knockdown
studies,
when
NQO1
was
overexpressed in H596 cells a
significant increase in invasion was
observed (Supplemental Figure
10).
Together
these
data
demonstrate that NQO1 levels are
critical for anchorage-independent
growth and the invasion of lung
cancer cells.
NQO1 depletion elevates ROS
levels and sensitizes cells to
anoikis.
Previous investigations have
shown that NQO1 can act as a
scavenger of ROS (192), thus we
hypothesized that depleting NQO1
in our lung cancer models would Figure 4. Depleting tumor-NQO1 levels increases ROS formation
increase endogenous levels of ROS. and sensitizes NSCLC to anoikis. In A and B, A549 shCtr-R, A549
shNQO1, H292 shCtr-L and H292 shNQO1-B cell lines were stained
As expected, our data show that with 5 µM DCFDA (Life technologies) to detect endogenous ROS
depletion of NQO1 in A549 cells levels (H O ). In C and D cell death ELISA assays (Roche Applied
Sciences) were performed on A549 and H292 NQO1 knockdown and
caused an increase in oxidative control cells as described in “Methods” to detect cells that had
stress as indicated by the increased undergone detachment induced cell death (anoikis). In A, p values for
shCtr-R vs A549 shNQO1 (p = 0.004). In B, p values for shCtr-L vs
DCFDA staining (a general ROS H292 shNQO1-B (p = 0.0012). In C, p values for A549 shCtr-R vs
indicator including H2O2 levels A549 shNQO1 (p < 0.0001). In D, p values for H292 shCtr-L vs H292
shNQO1 (p = 0.0001).
(Figures 4 A-B), supporting our
hypothesis that endogenous ROS
levels are increased in lung cancer cells when tumor-NQO1 levels are depleted.
2

2

In transformed cells the intracellular production of ROS is tightly regulated to prevent
programmed cell death (193). Excessive ROS production can lead to apoptotic
catastrophe, and cells that escape apoptosis are resistant to detachment induced cell
death, also known as anoikis (194). Anoikis resistant cells are capable of continued
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proliferation and distant tumor formation (195). Thus far, our data show that depleting
NQO1 prevents anchorage-independent growth and increases ROS stress levels.
Therefore, we further hypothesized that the inability of NQO1 depleted cells to grow in
an anchorage-independent environment was linked to anoikis sensitization caused by
increased levels of ROS. To test this hypothesis we performed cell death ELISA assays
on NQO1 knockdown cell models. Our cell death assays show that loss of NQO1 in
A549 and H292 cells significantly increased sensitization to anoikis (Figures 4C-D).
These data suggest that depletion of NQO1 expression in lung cancer cells increases
oxidative stress and potentiates
detachment induced cell death.
Depleting
tumor-NQO1
expression levels decreases
cell proliferation and in vivo
tumor growth.
Uncontrolled proliferation is
a
hallmark
of
malignant
neoplastic cells, thus novel
approaches
to
reduce
uncontrolled cell proliferation
are of paramount importance in
the development of anticancer
strategies. Our current data
show that loss of NQO1
decreases tumor growth in soft
agar
and
increases
sensitization to anoikis. Thus,
we hypothesized that depletion
of tumor-NQO1 levels would
significantly decrease the ability
of cells to proliferate. Our data
show that A549 and H292
NQO1 knockdown cells had
significantly lower rates of
proliferation as compared to
their
respective
controls
(Figures 5 A-B). These data
suggest that depletion of NQO1
inhibits cell growth by inducing
apoptosis
caused
by
detachment induced cell death.
To address the role that
NQO1 depletion plays in vivo
tumor
growth,
varying
concentrations (1, 2.5 and 5

Figure 5. Loss of NQO1 expression inhibits cell proliferation and in vivo
tumor growth. In A and B, A549 and H292 cells were assayed for
proliferation rates at 0, 24, 48 and 72 h using the CyQuant cell proliferation
kit (Life Technologies). In C, A549 shNQO1 cells (open symbols) and A549
shCtr-R (closed symbols) were subcutaneously injected into flanks of
athymic mice at varying concentrations ((1.0 black), (2.5 blue) or (5.0 red) x
6
10 ) cells. Tumor growth was assessed bi/weekly using calipers. In D, A549
shNQO1 and A549 shCtr-R cells were injected subcutaneously into flanks of
athymic mice and tumors were measured bi weekly by caliper measurements
3
until a volume of 1000 mm was reached. Kaplan-Meir survival analysis was
conducted using GraphPad Prism 6 software. In E, representative
photomicrograph of mice in C where mice were injected on the Left flank (L)
with A549 shNQO1 cells or on the right flank (R) with A549 shCtr-R cells at
the indication concentration of cells. Shown are mice whose tumors were
photographed after 32 days. In F, Western Blot for tumor-NQO1 expression
and PARP-1 cleavage. Samples were harvested in PARP-lysis buffer as
described in “Materials and Methods”. In A, p values for A549 shNQO1 vs
A549 shCtr-R cells at 24 h (p = 0.0031), 48 h (p < 0.0001) and 72 h (p =
0.0004). In B, p values for H292 shNQO1-B vs H292 shCtr-L cells at 24 h (p
= 0.0070), 48 h (p = 0.0011) and 72 h (p < 0.0001). In C, p values for A549
6
6
shNQO1 vs A549 shCtr-R cells at 5 x 10 cells (p <0 .0006), 2.5 x 10 cells (p
6
< 0.0006) and 1.0 x 10 cells (p<0.006). In D, p values for A549 shCtr-R vs
A549 shNQO1 (p = 0.0083)
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million) of A549 shNQO1 and A549 shCtr-R cells were implanted subcutaneously into
athymic mice and tumor growth and overall survival rates were evaluated. Our in vivo
xenograft data clearly show that a significant growth disadvantage is observed in A549shNQO1 cells at each concentration of cells implanted as compared to A549-shCtr-R
cells (Figures 5 C and E). In addition to significantly reducing in vivo tumor growth
rates, the depletion of tumor-NQO1 expression levels in animals bearing A549xenografts increased their overall survival as compared to animals bearing A549-shCtrR xenografts (Figure 5 D). We also observed that tumor-NQO1 levels remained
depleted in A549-shNQO1 xenografts as illustrated by our in vivo western-blot analysis
for NQO1 protein expression (Figure 5 F).
Interestingly, a substantial difference in
PARP-1 proteolysis was observed in A549shNQO1 tumors as compared to A549shCtr-R tumors, further supporting our
anoikis data that suggest that loss of
NQO1 leads to increased apoptosis
(Figure 5 F and Supplemental Figure
11).
NQO1 depletion reduces the percentage
ALDHhgh cells in the tumor cell
population.
We have shown that knockdown of
NQO1 expression in lung cancer cells
decreased clonogenic growth in vitro and
tumor growth in vivo. Numerous studies
have reported that cancer stem cell
populations are responsible for increased
tumorigenicity
and
resistance
to Figure 6. NQO1 depletion causes a decrease in
therapeutics. Thus, we sought to determine ALDH activity. In A, representative flow cytometry
of A549 shNQO1 and A549 shCtr-R cells analyzed
if NQO1 affected this critical population of tracing
for ALDH
activity using the Aldefluor Assay Kit from
cells. Previous work has shown that one of “Stem Cell Technologies”. Cells were assayed according to
manufacturers protocol as described in “Materials and
the most reliable cancer stem cell markers the
Methods”. DEAB was used as an inhibitor of ALDH
is aldehyde dehydrogenase (ALDH) (196, activity. The percentages shown in each tracing indicate
population of cells staining for ALDH
activity. In B,
197). Although several isoforms of ALDH the
graphical presentation of A549 shNQO1 and A549 shCtr-R
exists, a common assay used to define the cells assayed for ALDH activity. The graph represents
ALDH(high) stem cell population is the experiments repeated at least 5 times in duplicate.
Aldeflour assay (196). In our studies we
tested the hypothesis that NQO1 depletion caused less tumor growth due to depletion
of ALDH(high) cells. Our data clearly show that there is a significant decrease in the
ALDH(high) population in A549 shNQO1 cells as compared to A549 shCtr-R cells (Figure
6). Interestingly, this phenomenon was also discovered to be true in MiaPaCa
(Pancreas) and PC3 (Prostate) cancer cells (Supplemental Figures 12 and 13).
high

(high)

(high)

(high)

(high)

Discussion
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Normal cells are under continuous bombardment from intracellular and extracellular
oxidative stress in the form of ROS (198). Damage caused by uncontrolled oxidative
stress from lethal levels of ROS can lead to DNA strand breaks, mutation events and
even cell death (199). Thus, mechanisms that facilitate control over ROS levels are
uniquely important to cell proliferation and survival. Importantly, normal levels of ROS
are needed in various cell-signaling events involving cell proliferation as well as
programmed cell death. It is also of note that specific ROS are critical to many disease
processes such as aging and cancer (198, 199). Thus, various defense mechanisms
have evolved to regulate exposure to endogenous and exogenous ROS. These
mechanisms include the transcription factor Nrf2 that transcriptionally activates the
expression of numerous down stream target genes that modify and regulate the
duration and exposure level to ROS (200). The genes activated by Nrf2 include
glutathione peroxidase, catalase and NQO1. The down stream targets of Nrf2, such as
NQO1, regulate exposure to ROS from both exogenous and endogenous sources and
play a critical regulatory role in cell survival and cell death.
Cancer cells, just as in normal cells, must regulate ROS levels and have adapted to
exposure to high levels of ROS through the altered expression of specific ROS
regulatory genes that aid in their survival (201). Catalase for example, is normally
expressed at high levels in normal tissues, however in tumors its levels are relatively
low (202). The down-regulation of catalase expression in tumors is not clearly
understood. However, catalase suppression has been associated with specific tumor
promoting signaling pathways and resistance to chemotherapeutics (169, 203).
Interestingly, studies with breast cancer and lung cancer cells have shown that reexpression of catalase modifies their exposure to ROS levels from their tumor
microenvironment and ultimately enhances tumor cell death (204, 205). This would
imply that reversing the expression of specific ROS regulatory genes in cancer cells
could potentiate a tumor specific cell death.
Previous studies have implicated NQO1 as a prognostic marker that negatively
affects patient survival (137, 206). In most of these studies, the poor patient outcome is
attributed to the existence of 2 prominent NQO1 polymorphisms, referred to as *2 and
*3. The *2 mutation is more common and involves a C to T point mutation at nucleotide
position 609. These polymorphisms exist at varying, but small percentages, within the
population (171). Those patients whose tumors were identified to have the homozygous
*2 mutation in NQO1, were found to be more susceptible to issues involving
chemotherapeutic toxicity when exposed to NQO1-detoxified therapeutics such as
epirubicin (137). In contrast, recent retrospective analyses have shown that elevated
NQO1 expression in patient tumor versus normal tissue predicts poor patient survival
(185, 186). We hypothesized, from the latter studies, that tumors elevate NQO1 to
enhance survival and that reduction of NQO1 could potentially ameliorate the negative
effects of tumor-NQO1 overexpression on patient outcome.
In the current study we focused on determining whether decreasing elevated tumorNQO1 levels in lung cancer cells would inhibit tumor survival. We chose specific
readouts, such as anchorage-independent growth, anoikis and in vivo tumorigenesis
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assays, to make a connection between tumorigenic processes and the role that NQO1
played in each. Our data clearly show that loss of NQO1, by stable shRNA knockdown,
significantly affected anchorage- independent growth of lung cancer cells, which is
hallmark of tumorigenesis. These data suggested that NQO1 overexpression is
intimately involved in the survival and proliferative capacity of lung cancer cells that
overexpress NQO1. These data were corroborated by dicoumarol and Mac220 studies
that showed that treatment with NQO1 inhibitors significantly decreased the growth of
lung cancer cells in soft agar. In addition to inhibiting growth in soft agar, we showed
that loss of NQO1 potentiated anoikis, suggesting that cells that were NQO1 depleted
were more susceptible to detachment induced cell death. This was further supported by
the increase in ROS that was found in shNQO1 cells versus our control cells which
correlates with increased anoikis. We also showed that loss of NQO1 decreased both
cell proliferation and invasion suggesting that knocking down NQO1 decreases the
tumorigenic potential of lung cancer cells. In contrast to cancer cells, our in vitro data
show that transient knockdown of NQO1 in non-transformed, non-tumorigenic human
bronchial epithelial cells (HBECs) did not reduce their short-term viability or long-term
survival (Supplemental Figure 14).
Our in vivo studies confirmed that
stable NQO1 depletion increased
long-term survival in mice since
shNQO1 tumors were significantly
smaller than control tumors, and
survival of mice bearing shNQO1
tumors was significantly enhanced as
compared to mice bearing control
tumors. Finally, we show that loss of
NQO1 substantially reduced the
ALDH(high)
population
in
lung,
pancreas and prostate cancers. In
previous reports it has been
demonstrated that ALDH(high) activity
within a tumor population is a reliable
marker for cells that have a cancer
stem cell phenotype in a number of
malignancies
(196,
197).
Interestingly, knockdown of specific
ALDH isoforms has been linked to
the
loss
of
stemness
and
tumorigenicity in lung cancer (207).
Our studies show that loss of NQO1
reduces the population of cells with
ALDH(high) activity, suggesting that
the loss in tumorigenicity seen in
NQO1 knockdown cells (Figure 5 CE) is attributable to the loss of the

Figure 7. Model depicting therapeutic approach where
reduction of NQO1 levels in tumors leads to decreased tumor
burden in the lungs of cancer patients. In A, NQO1 (blue
squares) is expressed at normal levels in lung in response to
oxidative stress. In B, NQO1 (blue squares) is overexpressed in
tumor cells (black circles) within the lung due to increased necessity
to inhibit ROS stress. In C, targeting NQO1 in lung tumors leads to a
decrease in tumor burden in patients with elevated NQO1 levels in
their lung tumors. In B, cancer stem cells within a tumor will have
(high)
increased ALDH
activity. In C, NQO1 knockdown reduces the
(high)
population of tumor cells with ALDH
activity.

30

ALDH (high) subpopulation of cells (Figure 6). In summary, we report for that NQO1, a
gene found overexpressed in many solid tumors, including NSCLC, can be directly
targeted for therapy since it plays a critical role in the overall growth, invasive potential
and survival of lung cancer. We hypothesize that NQO1 expression is increased in
tumors to thwart ROS stress, and that reversing the elevated expression of tumorNQO1 leads to increased susceptibility to ROS and reduced tumor burden due to
anoikis and the loss of the ALDH(high) cell population (Figure 7). These results suggest
that NQO1 depletion may be an important link in eliminating cancer stem cell
populations not only in lung cancer, but in other malignancies as well. Finally, these
data establish the potential for a new clinical approach that targets NQO1 in lung cancer
patients whose tumor-NQO1 expression levels are often found to be 5-20 times more
elevated than the NQO1 levels in their adjacent normal lung tissue(170)
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Supplemental Figures

Supplemental Figure 1. Tumor-NQO1 overexpression leads to poor prognosis
in lung cancer patients. In A and B, Kaplan-Meier analysis of patient survival
based on tumor NQO1 expression levels from two different TCGA data sets. Data in
A included 148 high NQO1 patient tumors (red) and 145 low NQO1 patient tumors
(black) . Data in B are from 28 high NQO1 patient tumors (red) and 76 low NQO1
patient tumors (black) . Patients in these studies were grouped into NQO1 low and
NQO1 high expression groups as described in “Materials and Methods”.
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Supplemental Figure 2. shNQO1-B knockdown of NQO1 leads to decreased
growth in soft agar. In A, Western blot for NQO1 expression in A549 cells stably
knocked down for NQO1 using lentiviral (shNQO1-B) and compared to A549
parental, lentiviral vector control (shCtr-L) and A549 shNQO1 (retroviral)
knockdown cells. In B, A549-shCtr-L and A549-shNQO1-B cells were subjected
to soft agar assays as described in “Materials and Methods”. The soft agar data
presented here are represented in graphical form in Figure 2 C of the manuscript.
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Supplemental Figure 3. shNQO1-B knockdown of NQO1 in H292 cells
leads to decreased growth in soft agar. H292-shCtr-L and H292-shNQO1-B
cells were subjected to soft agar assays as described in “Materials and
Methods” for H292 cells. The soft agar data presented here are represented in
graphical form in Figure 2 D of the manuscript.
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Supplemental Figure 4. Dicoumarol inhibits growth of A549 cells in soft agar. In A,
Western Blot for NQO1 expression in A549 cells exposed to 50µM dicoumarol for 2 or 24
hours. A549 sh-NQO1 cells were used as negative control. In B, following dicoumarol
treatment, cells were liberated by trypsin, enumerated and subjected to soft agar assays as
described in “Materials and Methods”. In C, quantitative representation of soft agar plates that
were imaged after 3 weeks using an Epson V700 photo scanner. The enumeration of colonies
present in each dish was quantified using ImageJ software.
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Supplemental Figure 5. Mac220 inhibits growth of A549 cells in soft agar. In A, to
demonstrate the effect of Mac220 on an NQO1-dependent chemotherapeutic, A549 cells
were treated for 2 hours with varying doses of ARQ-761 (aka β-Lapachone, B-Lap) in the
presence or absence of the NQO1 inhibitor dicourmarol (DIC, 50 µM) or Mac220 (5 µM).
After 2 hours, drug media was removed and fresh media was added. Cells were allowed to
grow for 7 days prior to evaluation of survival using a Hoescht DNA content assays as
described previously (9,12). In B, following 24 h treatment with 50 µM dicoumarol or 5 µM
Mac 220, A549 cells were liberated by trypsin, enumerated and subjected to soft agar
assays as described in “Materials and Methods”. In C, quantitative representation of soft
agar plates that were imaged after 3 weeks using an Epson V700 photo scanner. The
enumeration of colonies present in each dish was quantified using ImageJ software.
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Supplemental Figure 6. Stable overexpression of NQO1 in H596 (NQO1
null) lung cancer cells causes increased growth in soft agar. In A,
Western Blot analysis of NQO1 null H596 cells that were stably transfected
with NQO1 using an LPC-NQO1 retro viral construct or vector control (LPCX) as described previously (9). In B, NQO1 enzyme assays were performed
according to the manufacturers protocol described in “Materials and
Methods” Shown is a representative quantification of NQO1 enzymatic
activity performed in triplicate. In C, cells were liberated by trypsin,
enumerated and subjected to soft agar assays as described in “Materials
and Methods”. In D, quantitative representation of soft agar plates that were
imaged after 3 weeks using an Epson V700 photo scanner. The
enumeration of colonies present in each dish was quantified using ImageJ
software.
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Supplemental Figure 7. Transient knockdown of NQO1 in H596 LPC-NQO1 cells
causes decreased growth in soft agar. In A, Western Blot analysis of H596 LPCNQO1 cells that were transiently transfected with NQO1 siRNA or scramble control
siRNA and harvested after 48 h as described in “Materials and Methods”. In B, following
transient transfections cells were liberated by trypsin, enumerated and subjected to soft
agar assays as described in “Materials and Methods”. In C, quantitative representation of
soft agar plates that were imaged after 3 weeks using an Epson V700 photo scanner.
The enumeration of colonies present in each dish was quantified using ImageJ software.
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Supplemental Figure 8. shNQO1-B knockdown of NQO1 in A549 cells
decreases cell invasion. In A, A549 shCtr-R and A549 shNQO1 cells were allowed
to form spheroids and the spheroids were placed atop of noble agar. The total area
was measured after 10 days of culture. In B, A549-shCtr-L and A549 shNQO1-B
cells were subjected to invasion assays as described in “Materials and Methods”.
Images and quantitation of invasion distance was performed as described in
“Materials and Methods”.
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Supplemental Figure 9. Stable overexpression of NQO1 in H596 NQO1-null
cells causes increased invasion. In A, H596 LPC-X and H596 LPC-NQO1 cells
were allowed to form spheroids and the spheroids were placed atop of noble agar.
Spheroids were then subjected to invasion assays as described in “Materials and
Methods”. In A and B, Images and quantitation of invasion distance was
performed as described in “Materials and Methods”.
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Supplementary Figure 10. Transient knockdown of NQO1 using siRNA
inhibits invasion of HCC1171 cells. In A, HCC1171 lung cancer cells were
transiently transfected with control siRNA or NQO1 siRNA as described in
“Materials and Methods”. After 48 h cells were harvested for Western
Assays to detect NQO1 expression. In B, following transfection cells were
enumerated and subjected to invasion assays as described in “Materials
and Methods”.
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Supplemental Figure 11. Stable knockdown of NQO1 in A549 cells causes loss
of PARP-1 protein expression. Western Blot analysis of A549 shCTr-R and
shNQO1 tumors harvested from mice at various times in long-term survival studies
(Figure 5 D). Samples were harvested in PARP-lysis buffer as described in
“Materials and Methods” and probed for PARP-1 and NQO1. Blots were also probed
with β–actin to determine loading equivalence.
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(high)

Supplemental Figure 12. Knockdown of NQO1 reduces ALDH
activity
in Pancreas cancer cells. In A, representative flow cytometry tracing of
(high)
MiaPaCa shNQO1 knockdown cells and shCtr-R cells analyzed for ALDH
activity using the Stem Cell Kit from “Stem Cell Technologies”. Cells were
assayed according to manufacturers protocol as described in “Materials and
(high)
Methods”. DEAB was used as an inhibitor of ALDH
activity. In B, graphical
(high)
representation of shNQO1 and shCtr-R cells assayed for ALDH
activity.
Graph represents experiments repeated at least 5 times in duplicate.
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(high)

Supplemental Figure 13. Knockdown of NQO1 reduces ALDH
activity in
Prostate cancer cells. In A, representative flow cytometry tracing of PC3 shNQO1
(high)
knockdown cells and shCtr-R cells analyzed for ALDH
activity using the Stem Cell
Kit from “Stem Cell Technologies”. Cells were assayed according to manufacturers
protocol as described in “Materials and Methods”. DEAB was used as an inhibitor of
(high)
ALDH
activity. In B, graphical presentation of shNQO1 and shCtr-R cells assayed
(high)
for ALDH
activity. Graph represents an experiment performed in triplicate.
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Supplemental Figure 14. NQO1 knockdown does not inhibit short-term
viability our long-term survival of non-transformed human bronchial
epithelial cells. In A, high levels of NQO1 activity are detected in A549 cells as
compared to the low levels detected in the non-transformed, non-tumorigenic
human bronchial epithelial cells (HBECs) using an NQO1 activity kit (ABCAM) as
described in “Materials and Methods”. In B, Western-blot analyses of HBECs for
NQO1 expression following a 48h transient transfection with scramble control
siRNA or siRNA-NQO1 (Santa Cruz Biotech). In C and D, representative images
of soft agar assays comparing tumorigenic A549 cells and non-transformed and
non-tumorigenic HBECs (performed in triplicate) and quantitation of the colonies
detected. In E, HBECs were subjected to transient transfections with siRNAControl or siRNA-NQO1 (SantaCruz Biotech). After 48h, cells were enumerated
and seeded at a density of 20,000 cells/well in 96 well plates for 24 h. The
following day short-term viability assays were performed using CellTiter-Glo
reagent (Progmega). Luminescence was detected using a Synergy-H1 Hybrid
microplate reader. Relative Luminescence Units were calculated by subtracting
the blank (media alone) wells from the test wells. In F, HBECs were subjected to
transient transfections with siRNA-Control or siRNA-NQO1. After 48 h cells were
seeded in 48 well dishes at a density of 2500 cells/well. Cells were allowed to
grow for 7 days. After 7 days, long-term survival based on DNA content was
detected using a Hoescht staining fluorescence assay described in “Materials and
Methods”. Fluorescence was detected using a Synergy-H1 Hybrid microplate
reader. Relative Fluorescence Units were determined by subtracting blank wells
containing Hoescht only from test wells.
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Abstract
Cancer stem cells (CSCs) are purportedly a key resistance factor in most solid tumor
models. Stem cell markers for heterogeneous bulk tumors have been loosely defined in
the literature for most tumor types with albeit some consensus as to which assays are
useful in determining whether specific genes are playing roles in the cancer stem cell
phenotype. In the current study we utilized a tumor spheroid model to determine
whether NADPH quinone oxidoreductase-1 (NQO1) was requisite in the promotion of
the cancer stem cell phenotype in non-small cell lung cancer (NSCLC). Our data show
that stable depletion of NQO1 in A549 and H358 human NSCLC tumor models alters
their ability to form primary tumor-spheroids. In addition to inhibiting primary spheroid
formation, the loss of NQO1 also affected serial, secondary and tertiary, spheroid
formation. Interestingly when NQO1 expression levels were rescued the spheroid
formation ability of tumor cells was restored. Our data also show that A549 and H358
tumor spheroids were significantly less proliferative when NQO1 was depleted as
compared to control cells. Finally, our data also show that cisplatin refractory A549
tumor spheroids were rendered significantly sensitized to cisplatin due to NQO1
depletion, suggesting that removal of NQO1 reduces the stem cell resistant population.
In summary, the data from these studies, along with our previous findings that show
NQO1 depletion reduces ALDHhigh activity, strongly support a role for NQO1 as marker
for the CSC phenotype in NSCLC.
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Introduction
Over the past two decades lung cancer has been the leading cause of cancer related
deaths in the U.S. and worldwide (208). In 2016 it is estimated that more than 158,000
deaths will occur in the U.S. due to cancer of the lung and bronchus (209). Of the
221,000 estimated new lung cancer cases that will occur in 2016, 20% will be
diagnosed as small cell lung cancer (SCLC), with the remaining 80% developing nonsmall cell lung cancer (NSCLC) (209-211). Both NSCLC and SCLC have abysmal 5year survival rates of 15% and 5 % respectively (208, 209). The major factors leading to
the poor survival rates observed in lung cancer patients include chemo-resistant
disease, late stage diagnosis and subsequent spreading of disease (212, 213).
Interestingly, a number of NSCLC cases have demonstrated that overexpression of
cytoprotective genes reduces the effects of commonly prescribed chemotherapeutics
and radiation therapy (146). Of those genes with increased expression,
NAD(P)H:quinone oxidoreductase 1 (NQO1), has been found to be overexpressed in
~60% of all NSCLC cases (117, 214). Additionally, the presence of lung cancer stem
cells (CSCs) has become increasingly appreciated as a mechanism to enhance the
tumorigenic properties of NSCLC. The ability of CSCs to initiate tumorigenesis,
circumvent conventional therapies, and metastasize to distant locations makes targeting
CSCs a promising strategy in the fight to improve patient survival.
NQO1 is a phase II detoxifying enzyme that is responsible for the neutralization of
dangerous intracellular quinones, and in general serves to scavenge reactive oxygen
species (ROS) (192, 215). Recently, there has been increased attention given to NQO1
overexpression in a number of tumor malignancies as it has been shown to be a useful
therapeutic target. Treatment with the quinone analog, β-lapachone (currently ARQ-761
in clinical trials), has shown promise inducing death in a tumor-specific manner. ARQ761 enters into a futile cycle with NQO1 that leads to ROS accumulation, poly ADP
ribose polymerase hyperactivation, nucleotide depletion, and ultimately cell death (170,
175, 216). While substantial data exists to support NQO1 overexpression as a valid
drug target, the mechanism by which NQO1 promotes the tumorigenic phenotype is not
well understood.
In 1997, Bonnet and Dick were the first to describe the concept of a cancer stem cell
when they demonstrated that a small leukemic cell population, defined by a set of
cluster differentiation markers (CD34+CD38-), were able to establish the disease at low
numbers in comparison the whole tumor population (217). Since the original
identification of a leukemic CSC, researchers have discovered and defined CSCs in a
number of other malignancies including breast, brain, and prostate cancers (218-220).
To this point, a number of CSC markers have been used in an attempt to define the
CSC population in NSCLC including CD133, aldehyde dehydrogenase (ALDH), and
side population (221-223). Of the large number of markers used to define NSCLC
CSCs, ALDH activity has shown the most promise in defining the small tumorigenic
population, and because of this it has become the focus of a great amount of CSC
research.
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In an attempt to better
understand
NQO1’s
role
in
tumorigenesis
and
tumor
maintenance, our laboratory has
begun
to
investigate
the
relationship between NQO1 and
maintenance of the cancer stem
cell-like phenotype (Figure 1).
Previously, we published that
NQO1 is important for a number of
malignant characteristics including
tumorigenesis, anoikis resistance,
invasion, and even regulation of
ALDH activity (224).

Figure 1. Characteristics of cancer stem cells and their
progenitors. Cancer stem cells are believed to responsible for giving
rise to the heterogeneous tumor population, as well as maintain an
infinite pool of cancer stem cells through the processes of asymmetric
and symmetric division, respectively. The two distinct populations that
arise from these divisions include the cancer stem cell population (beige
cell), as well as the progenitor population (blue cell). Cancer stem cells
harbor a number of traits including self-renewal capabilities, tumor
initiation, metastatic potential, chemoresistance, and maintenance of an
undifferentiated phenotype. In contrast, the progenitor population is
believed to be non-tumorigenic, differentiated, and susceptible to
therapy

To expand upon the novel
findings that showed the activity of
the stem cell marker ALDH was
reduced, suggesting less cancer
stem-like cells, we have conducted
new studies that link NQO1 as
having a vital role in the CSC
phenotype of NSCLC. Here, we
demonstrate that NQO1 is necessary for in vitro serial spheroid formation, therapeutic
resistance, and in vitro limiting dilution tumor formation. Our data demonstrate for the
first time that NQO1 is vital to the maintenance of the CSC population and that reducing
NQO1 expression levels in tumors may prove to be a useful therapeutic approach for
reducing chemo-resistant NSCLC CSC.
Materials and Methods
Cell Culture
A549, H358, and H596 cell lines were grown in Dulbecco’s Modified Eagles Media
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% L-glutamine. Cell
lines were cultured at 37° C with 20% oxygen and 5% carbon dioxide prior to spheroid
culture. Cells were passaged weekly and supplemented with fresh media.
Stable NQO1 protein knockdown
A549 and H358 cell lines underwent stable NQO1 knockdown as previously
described (224). Briefly, the shNQO1 retroviral vector was purchased from Open
Biosystems (RHS1764-9691437), and lentiviral particles were purchased from Santa
Cruz Biotechnology (sc-37139). The stable knockdown cell lines (shNQO1, shNQO1
[lenti]) and empty vector controls (shCtr, shCtr [lenti]) were created for both A549 and
H358 cell lines by viral infection in polybrene supplemented media containing either
shNQO1 or shCtr viral particles. Following viral infection, cells were then put in limited
dilution under puromycin (2 µg/ml) selection, and screened for NQO1 expression via

50

Western blot. A549-shNQO1 and H596 cell lines were forced to express NQO1 via the
retrovrial vector (LPC-NQO1) or the empty vector control (LPC-X) as previously
described. Cells were then put into limited dilution and evaluated for NQO1 expression
via Western blot.
Western blotting
Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room
temperature, and then incubated overnight with β-actin (1:5000, Santa Cruz
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa
Cruz Biotechnology), as well as 1:1000 dilutions of monoclonal Shh, SOX2, and Nanog
antibodies (Cell Signaling). Pierce ECL western blotting substrate (Thermo Scientific)
was used to visual bands on Hyblot-CL autoradiography film (Denville Scientific)
NQO1 Activity Assay
NQO1 enzyme activity was performed as previously described (224). Briefly, 2x107
cells of each cell line were collected. Pellets were solubilized in extraction buffer for 20
min, after which they were centrifuged at 18,000 x g for 20 min at 4° C. Supernatants
were collected into eppendorf tubes at stored at -80° C. Samples were then run
according to the manufacturers protocol for the NQO1 activity assay kit from Abcam.
Results were read at an absorbance of 440 nm every 20 seconds for 5 minutes utilizing
the Synergy-H1 Hybrid microplate reader. Plates were shaken both before and after
each reading.
Spheroid Formation
Low-attachment culture plates were produced by coating the plates (Corning) with a
0.2% poly-hema/95% ethanol solution. Plates were incubated at 60° C overnight and
allowed to dry. The process was then repeated a second time. Plates were washed
twice with milli-Q water immediately prior to use. Cells were trypsinized and treated with
trypsin neutralizing solution (1:1 ratio) prior to being counted using a hemocytometer.
160,000 cells were then plated in the low attachment 150 mm plates in 0.25% FBS
DMEM supplemented with 1% L-glutamine. Cells were allowed to form spheroids over
14 days, at which time they were collected, trypsinized into single cell suspensions, and
utilized for the respective assay. For spheroids grown in methylcellulose suspension,
1% methylcellulose in 0.25% FBS DMEM was further diluted in 1:1 0.25% FBS DMEM
and cells were added to this mixture. The cell suspension was then plated on low
attachment plates and imaged 2 weeks later for quantification.
Extreme limited dilution assay
Low attachment 96-well plates were prepared by treating plates with 0.2% polyHEMA in 95% ethanol and allowing them to dry overnight. This process was repeated a
second time to ensure proper application. Prior to plating the 96-well plate was washed
twice with sterile milli-Q water. Cells were trypsinzed, counted, and plated in 0.25%
FBS-containing DMEM at densities of 40, 120, 360, and 720 cells per well. Each dilution
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was performed in 24 wells. Cells were allowed to expand over three weeks (21 days), at
which time the wells were examined for the presence of spheroids. A well containing a
spheroid was counted as one, multiple spheroids per well did not increase the number
of positive wells. The number of positive wells per dilution was then entered into the
extreme limited dilution cancer stem cell frequency calculating software available at
http://bioinf.wehi.edu.au/software/elda/.
Drug Treatment Studies
Spheroids were collected after 14 days and trypsinized into single cell suspension.
Cells were counted and suspended in DMEM media supplemented with 0.25% FBS and
1% L-glutamine at a concentration of 10,000 cells/ml. 200 µl of cell suspension was
then added to each well. Cells were allowed to attach overnight, and the following day
were treated with 0, 2.5, 5, and 10 µM cisplatin dissolved in DMSO. Stock
concentrations of 2.5, 5, and 10 mM cisplatin were diluted 1:1000 in 0.25% FBS DMEM
supplemented with 1% L-glutamine and incubated on cells overnight. Each dose was
performed in 8 replicates for each dose tested. Twenty-four hours after initial treatment,
cell viability was assessed using Cell-Titer Glo (Promega), according to the
manufacturer’s protocol utilizing the Synergy-H1 Hybrid Reader.
Cell Proliferation Assays
Spheroids were mechanically (pipetting) and enzymatically (trypsin) broken down
into single cell suspension. Cell suspension was then treated 1:1 with trypsin
neutralizing solution to inactivate the trypsin. Cells were then quantified using a
hemacytometer and suspended in 0.25% FBS DMEM at a concentration of 10,000
cells/ml. Utilizing 96-well plates, 100 µL of each cell suspension was plated in 5 wells,
and the respective plate was collected at the time points of 0, 24, 48, and 72 hrs. At this
time 1e6 cells was also collected in a micro-centrifuge tube in order to later generate a
standard curve. Collected plates were washed once with PBS, aspirated, and froze at 80° C, until all plates were collected and ready to be read. Plates were quantified using
CyQuant Cell Proliferation Assay (Thermo Fisher), according to the manufacturers
protocol utilizing the Synergy-H1 Hybrid Reader.
Quantitative real-time qRT-PCR
Total RNA was isolated utilizing the Trizol extraction method (225). cDNA was
created from the total RNA sample utilizing iScript cDNA Synthesis Kit (Bio-Rad). qRTPCR was performed using primers designed for NQO1 (Fwd- 5’CCAGATATTGTGGCTGAACAAA-3’; Rev- 5’-TCTCCTATGAACACTCGCTCAA-3’),
and SsoAdvanced Universal SYBR Green Supermix (Bio-Rad). Samples were analyzed
using the CFX Connect Real-time qRT-PCR System (Bio-Rad). Relative expression
values were calculated utilizing double delta Ct analysis.
Statistical analysis
Data analyses were performed using GraphPad Prism 6 software. Statistical
significance was determined by using the Student t tests, and P values from these
analyses were reported. Differences were considered significant when P values were <
0.05.
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Results
NQO1 is essential for in vitro spheroid formation
In order to evaluate the stemness of a cancer cell population, it is common to utilize
the spheroid formation assay as it demonstrates the ability of cells to replicate in a
detached environment, one of the hallmarks of the transformed phenotype (46, 226228). To determine the role of NQO1 in stemness using spheroid assays as an
assessment tool, NQO1 levels were
reduced in both the A549 and H358
NSCLC cell lines via the stable
retroviral expression of shRNA toward
NQO1, (Figures 2A & 2C) respectively.
As expected from our previous
experience in creating stable NQO1
knockdown cell lines, the reduction in
NQO1 protein expression correlated
with a decrease in NQO1 activity
(Figures 2B & 2D). Subsequently, we
demonstrated that the reduction of
NQO1 protein levels leads to a near
total loss in primary spheroid formation
in A549 (Figure 3A) and H358 (Figure
3C) cell lines. A549-shCtr cells were Figure 2. Stable knockdown of NQO1 expression in NSCLC
able to form ~30 spheroids per field of cells reduces NQO1 activity. In A, A549 lung adenocarcinoma
were evaluated for NQO1 expression following retroviral
view (50X magnification), where the cells
transfection of shRNA targeted at NQO1 (A549-shNQO1), or
A549-shNQO1
population empty vector control (A549-shCtr). In B, A549-shCtr and A549cell lines were analyzed for NQO1 activity, where loss
demonstrated a significantly reduced shNQO1
of NQO1 correlated with a significant decrease in NQO1 activity
ability to produce spheroids (Figure (**** = p <0.0001). In C, the lung cancer cell line, H358 was
for NQO1 protein expression following retroviral
3B). Interestingly, the inability of A549- evaluated
transfection of shRNA directed toward NQO1 (H358-shNQO1),
shNQO1 cells to form spheroids was or the empty vector control (H358-shCtr). In D, H358-shCtr and
cell lines were evaluated for NQO1 activity, and
not a result of significant cell death, as H358-shNQO1
demonstrated that loss of NQO1 protein expression correlated
trypan blue exclusion assays and with a significant decrease in NQO1 actvity (**** = p <0.0001; ***
analysis of apoptotic endpoints (PARP- = p 0.0001).
1 cleavage and AIF expression), show
no significant difference over time (Supplemental Figure 1). Additionally, this data was
recapitulated using a second, lentiviral driven shRNA toward NQO1 with similar results
(Supplemental Figure 2A) The H358 cell line does not appear to have a robust sphere
forming ability as compared to A549 cells as they form fewer spheres per field of view.
However, a significant difference exists between the H358-shCtr and H358-shNQO1
populations (Figure 3D). To confirm that our spheroids were forming because of clonal
expansion and not forming due to aggregation, we also formed spheroids using
methylcellulose and found a similar significant difference in spheroid forming ability in
A549 cells that were depleted in NQO1 expression versus controls (Supplemental
Figure 2B). In an effort to further confirm NQO1’s importance in spheroid formation, the
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NQO1 inhibitor, dicumarol, was added to the media
of A549-shCtr and H358-shCtr cultures and
monitored for sphere formation (Supplemental
Figure 3).

Figure 3. NQO1 depletion reduces primary
tumor spheroid formation. In A and B, are
representative images of primary spheroid
formation for both A549 and H358 cell lines,
respectively. A549-shCtr cells (A, top panel)
robustly form primary spheroids in comparison
to the A549-shNQO1 cell lines (A, bottom
panel). In the H358 cell line, again the H358shCtr cell line (B, upper panel) has an
increase in the number of primary spheroids
formed in comparison to H358-shCtr (B, lower
panel). Primary spheroid counts are quantified
for A549 and H358 in C and D, respectively
(**** = p <0.0001; *** = p =0.0035).

In addition, we validated the spheroid assay as a
method by which to enhance the CSC population
through the evaluation of the known stem cell
markers, Sox2, Shh, and Nanog. We determined
that spheroid culture increased the expression of
each marker in comparison to normal (attached)
culture conditions, that was subsequently
decreased
following
differentiation
culture
conditions in 10% FBS containing media
(Supplemental Figure 4). These results thus
validate the spheroid culture method as a means to
enhance the CSC population in vitro.

Interestingly, when we evaluated the expression
of NQO1 in spheroids, we noticed the expression of
NQO1 protein in the A549-shNQO1 population
remained reduced in comparison to A549-shCtr
spheroid cells (Supplemental Figure 5A), however
there was an increase in NQO1 mRNA in the A549shNQO1 population, as determined by real-time
qRT-PCR (Supplemental Figure 5B). The level of
NQO1 mRNA expression remained significantly
reduced in comparison to the A549-shCtr cell line, however a significant increase was
noted in comparison to A549-shNQO1 cells plated in 2D culture (A549-shNQO1 2D).
These results indicated that NQO1 expression may be vital to spheroid formation, as
those A549-shNQO1 cells that are capable of forming spheroids have a robust increase
in NQO1 expression in comparison to A549-shNQO1 cells grown in attached conditions.
Additionally, this data demonstrate that the spheroid culture enhances the CSC
population, and that NQO1 reduction severely inhibits the ability of NSCLC cell lines to
initiate spheroid formation.
NQO1 is necessary for serial in vitro sphere formation
CSC properties include the ability to divide asymmetrically in order to continually
produce both a CSC population as well as a population of proliferative progenitor cells
(229). This allows for the CSC population to continually perpetuate its tumor-initiating
capabilities following gross reduction of total tumor cell numbers. In an effort to
demonstrate the presence of CSCs within the A549 and H358 cell lines, serial tumor
sphere formation assays were performed. Primary spheres were collected and single
cell suspensions were made that were then placed back into the sphere forming assays.
This process was carried out until tertiary spheres were formed. Given that both the
A549-shNQO1 and H358-shNQO1 cells were severely hindered in their primary sphere
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formation, it was not surprising that their
ability to form secondary and tertiary
spheres was also restricted (Figures 4A &
4B, respectively). In the case of the A549
cell line, secondary and tertiary A549shNQO1 spheres formed at significantly
lower numbers than A549-shCtr cells.
These data clearly show that there exists
an essential role for NQO1 in serial
perpetuation of tumor spheres. This finding
is further supported by data obtained from
the H358 cell line. H358-shCtr cells show a
slight increase in the sphere forming ability
upon serial plating, where H358-shNQO1
lose tertiary sphere forming abilities, a
more supportive finding for NQO1’s role in
serial sphere formation than what is seen
in A549 cells. Interestingly, in a second
H358-shNQO1 clone that has greater
expression of NQO1, primary sphere
formation remains equal to what is seen in
controls (Supplementary Figure 6). These
data suggest the possibility that a threshold
of NQO1 expression exists which allows
serial formation of tumor spheres.

Figure 4. Loss of NQO1 expression reduces serial
spheroid formation, and re-expression of NQO1
rescues tumor-spheroid forming ability. The selfrenewal capabilities of lung cancer stem cells were
assayed via a serial spheroid formation assay. In A, A549shCtr cells form similar numbers of spheroids in primary
(black bars), secondary (light grey bars), and tertiary
generations (dark grey bars), where the A549-shNQO1
cells form significantly fewer spheroids in each generation
(* = p =0.0018, # = p = 0.0102, ∞ = p < 0.0001). The H358
cell line, as seen in B, shows similar results (* = p =0.0035,
# = p = 0.0449, ∞ = p < 0.0001). In C, Western blot
analysis of A549-shNQO1 cells transfected with the
retroviral NQO1 vector in an effort to induce re-expression
of NQO1 protein. In D, primary spheroid formation in NQO1
re-expressing A549-shNQO1 cells. The rescued NQO1
expression induced a significant increase in the formation
of primary spheroids (p = 0.0121).

In addition to serial spheroid assays,
NQO1 rescue experiments were performed
to
definitively
demonstrate
NQO1’s
necessity in spheroid formation. A549shNQO1 cells were forced to express
NQO1 via retroviral vector, or the empty
vector control. It can be seen in Figure 4C
that the level of NQO1 expression is comparable to parental A549 cell line (left panel),
and the re-expression of NQO1 results in a significant increase in spheroid formation in
comparison to the control vector (Figure 4D). Furthermore, we utilized the NQO1-null
NSCLC cell line, H596 that harbors the *2 polymorphism. We then drove the expression
of NQO1 utilizing the retroviral NQO1 vector and evaluated the sphere forming ability in
comparison to the empty vector control (Figure 5). These results recapitulate what was
observed when NQO1 levels were rescued in the A549 cell line that is the presence of
NQO1 significantly increases the sphere forming ability of H596 LPC-NQO1 cells in
comparison
to
its
H596
LPC-X
(NQO1-null)
control.
Limited dilution assays are often performed in order to determine the tumor initiating
cell frequency within a cell population (228). In order to determine the frequency of
CSCs within the A549 and H358 cell lines, both cell lines were placed in an extreme
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limiting dilution assay. Results from this
assay demonstrate that in the A549 cell
line, those cells in which NQO1 is present
have an approximate 12-fold increase in
the presence of cancer stem cells in
comparison to the shNQO1 cell line. This
was also true for the H358 cell line
however to a lesser degree (~ 2-fold)
(Table 1). These results suggest that
NQO1 is vital to maintenance of the cancer
stem cell population, which is in agreement
with previously published data (224).

Figure 5. Overexpression of NQO1 in NQO1 null H596
cells enhances tumor spheroid formation. The NQO1
null lung cancer cell line was forced to over-express NQO1
via retroviral vector and subjected to the spheroid formation
assay. NQO1 expression in the LPC-NQO1 cell line was
confirmed via Western blot in A. In B, the numbers of
spheroids formed per field of view were quantified in the
parental, LPC-X, and LPC-NQO1 H596 cell lines. In C,
representative images corresponding to the quantification
found in B (** = p =0.0007; ** = p= 0.0078).

NQO1 knockdown inhibits proliferation,
increases chemotherapeutic resistance
of NSCLC tumor spheroids
Increased cellular proliferation is often
observed in tumor cells and previous
studies
have
indicated
the
rapid
proliferative capacity in various lung cancer
cells. However, we assessed the
proliferative capacity cells that were no
longer attached to plastic to determine if
NQO1 expression mattered in the cells
ability to grow in 3D-tumor spheroid
culture. Our results show that indeed
NQO1 expression mattered since tumor

spheroid
shCtr
cells
were
significantly more proliferative as
compared to shNQO1 cells for
both A549 and H358 cell lines
(Figures 6A and 6B).
A hallmark of the CSC
phenotype
is
the
inherent
resistance to chemotherapy. Given
that NQO1 has been described to
protect against chemotherapy in
malignant cells, as well as
protecting
in
chemotherapyinduced toxicities in normal cells,
we hypothesize that spheroids
expressing NQO1 will be protected
against cisplatin induced cell death
(146, 167, 230-232). In order to
test
this,
spheroids
were

Table 1. Cancer stem cell frequency in A549 and H358 cells with or
without shNQO1 expression. Quantification of the number of cancer
stem cells present in the cell populations that have been examined was
carried out utilizing an in vitro extreme limited dilution assay. This assay
requires plating limited dilutions of cells in low attachment conditions,
and examining wells for spheroid formation. Wells with at least one
spheroid were counted as a positive well for the corresponding dilution.
The results were then analyzed using Extreme Limited Dilution Analysis
(ELDA) software. The resulting CSC frequencies demonstrate a marked
increase in the CSC population found in A549-shCtr and H358-shCtr in
comparison to their respective shNQO1 cell lines.
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dissociated into single cell
suspension and plated at a
density of 1,000 cells per well in
a 96-well plate. The following
day, the media was removed and
media containing 0, 2.5, 5.0, or
10 µM cisplatin was added to the
cells. The treatment of tumor
spheroids with cisplatin lasted 24
h, after which the Cell-Titer Glo
kit was used to measure cell
viability. The data presented in
Figures 6C and 6D demonstrate
that for both A549 and H358
spheres, the expression of
NQO1 protects against the
cytotoxic effects of cisplatin at all
doses administered. The control
groups for both cell lines were
used to normalize the data, as
there was an observed increase
in viability (greater than 100%
viability, data not shown), which
is most likely due to an increase
in cell numbers. These data
suggest that specific refractory
subpopulations
within
bulk
NSCLC tumors are resistant to
chemotherapeutics in part due to
NQO1 expression levels, and
that
cisplatin-resistant
populations of CSC within A549
and H358 bulk tumors could be
reduced by NQO1 depletion
strategies.

Figure 6. NQO1 depletion increases sensitization to cisplatin
treatment and inhibits spheroid-cultured cell proliferation. In A, A549shCtr and A549-shNQO1 primary spheroids were dissociated, plated, and
subsequently treated with cisplatin the following day at the given
concentrations. Cell viability was computed by comparing the percent of
A549-shNQO1 survival to that of the A549-shCtr cell line. After 24 hours of
cisplatin exposure, there was a significant difference in the surviving
fraction of cells in the A549-shCtr population in comparison to the A549shNQO1 cell line (* = p <0.05; ** = p =0.0076). In B, the same experiment
was carried out comparing the H358-shCtr and H358-shNQO1 cell lines
with similar results, where the H358-shNQO1 cell line was more
susceptible to cisplatin treatment than the H358-shCtr cell line (** = p
<0.005). In C, A549-shCtr and A549-shNQO1 cells grown in spheroid
conditions were assayed for cellular proliferation. Spheroid cells were
plated, collected at the specified time points, and enumerated using the
CyQuant Cell Proliferation Assay (Thermo Fisher). At each time point a
significant reduction in cell numbers was observed (* = p <0.05). In D, the
same cell proliferation assay was carried out using the H358-shCtr and
H358-shNQO1 cell lines. Here, again, there exists a statistically significant
reduction in cell proliferation in the H358-shNQO1 cell line in comparison
to the H358-shCtr cell line (* = p <0.05).

Discussion
It is generally accepted that a tumor is a population of many diverse cells that have
various roles in the survival of the heterogeneous bulk tumor (233, 234). One
purportedly critical cell type/population within the bulk tumor is thought to be the tumorinitiating cell or CSC that gives rise to chemoresistant cell populations, and are thought
to be responsible for latent disease resulting in tumor recurrence, metastasis and poor
prognoses (235-237). This specialized population of cells is understood to have features
similar to those of normal stem cells including the ability to repopulate an entire
population of diverse cell types. Thus, CSCs allow the continual self-renewal and
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propagation of the CSC population. Many scholarly endeavors have been made over
the past thirty years to identify and characterize the CSC phenotype within each tumor
type. These efforts have led to the development of new therapeutic strategies for
treatment of various cancers (238-240).
The identification and dissociation of the cancer stem cell population from the bulk
tumor population has been primarily accomplished using markers for stemness.
Although no iron clad pattern has developed over the years to allow a cook book
determination of which population of cells within a bulk tumor represent the CSCs for
that tumor, many studies have developed protocols using various stemness markers as
strategies to collect these unique cell population. In breast cancer the most common
stemness markers used in the isolation of CSCs include CD44high CD24low populations
as well as populations that express ALDHhigh activity and SOX2 expression (241, 242).
While in lung cancers ALDHhigh activity, along with Notch expression have been more
closely linked to CSC population in lung cancer patients whose tumors recur,
metastasize and are refractory to therapy (196, 243).
In addition to the heavy utilization of CSC markers, various tissue culture and
propagation methodologies have been developed to isolate or enrich for CSC
populations. For example, the 3D tumor spheroid model has become a staple amongst
assays used to study drug efficacy, as well as the CSC phenotype. The spheroid model
is believed to be more representative of tumor growth in vivo and thus its utilization has
expanded to involve drug efficacy studies as well as isolation of CSC for analysis (35,
244).
In our recent studies we showed that NQO1 depletion in the general population of
A549 and H292 NSCLC tumor cells correlated with loss of ALDHhigh activity (224). We
also found that NQO1 depletion inhibited proliferation, invasion and growth in vivo.
Those data were the first to indicate that tumor-NQO1 levels were linked to
tumorigenesis, and that NQO1 may be associated with the CSC phenotype. In the
current study we compared tumor spheroid forming ability in cells with or without NQO1.
In both our shNQO1 knockdown models we found that NQO1 depletion reduced the
ability of NSCLC cells to form tumor spheroids and their subsequent ability to form
secondary and tertiary spheroids was significantly inhibited by the loss of NQO1.
Interestingly when NQO1 was rescued in our NQO1 knockdown cell lines tumor
spheroid formation was restored. In addition to NQO1 rescuing NQO1 knockdown cell
lines, we also show that establishing NQO1 expression in NQO1 null cell lines allowed
for a significant increase in the spheroid forming ability of NQO1 null NSCLC cell line
H596.
In support of NQO1 enhancing the CSC population, we demonstrate that spheroid
culture enhances the expression of known stem cell markers SOX2, Shh, and Nanog.
Interstingly, these results are observed in both our A549-shCtr and A549-shNQO1 cell
lines. When evaluating the expression of NQO1 in our spheroids we notice an
increased, yet significantly less, expression of NQO1 in our A549-shNQO1 cell line in
comparison to control. This argues the point that in order for A549-shNQO1 to survive
and expand under spheroid conditions, increased expression of NQO1 is vital. We
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postulate that the increased expression of NQO1 in our knockdown line is the reason
we observe spheroid formation in the A549-shNQO1 cell line and an increase in stem
cell markers during spheroid culture. These data and the loss of ALDHhigh activity in our
previous work, strongly suggest that NQO1 is a CSC marker for NSCLC.
Finally, we investigated the effect that NQO1 depletion had on chemotherapeutic
resistance using tumor spheroids. Our data show that shCtr spheroids were resistant to
cisplatin while shNQO1 spheroids were sensitized to cisplatin treatment. These data
suggest that depleting NQO1 expression reduces the drug resistant cell population from
the population of cells rendering them more sensitive to chemotherapy.
In summary our data provide a sound rationale for developing therapeutics for
tumors that overexpress NQO1 focusing on decreasing NQO1 expression to eliminate
the CSC population. Possible strategies may include tumor targeted siRNA strategies to
decrease the NQO1 overexpressing population in vivo.
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Supplemental Figures

Supplemental Figure 1. Spheroid culture does not affect cell viability. In A,
the viability of cells in spheroid culture was evaluated via trypan blue exclusion
over the two-week culture period. There was no obvious difference in cell
viability between the A549-shCtr and A549-shNQO1 cell lines at anytime over
the course of observation. In B, cells in spheroid culture were evaluated for
apoptosis induction by evaluating PARP1 cleavage, as well as AIF induction.
A549 treated with 0.5 uM staurosporin [A549 (0.5 µM Stauro] served as a
positive PARP1 cleavage positive control. There was no apparent induction of
PARP1 cleavage, as well as no obvious increase in AIF expression over the
spheroid culture period.
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Supplemental Figure 2. Loss of NQO1 via lentiviral shRNA inhibits
spheroid formation, and spheroid formation is a result of clonal
expansion. In A, Western bot analysis of lentiviral-shRNA knockdown of NQO1
[A549-shNQO1 (lenti)] in comparison to the A549 control cell line [A549shNQO1 (lenti)] (left panel). In B, spheroid assay of A549-shCtr (lenti) and
A549-shNQO1 (lenti) demonstrating a significant loss of spheroid formation with
NQO1 reduction (** = p = 0.0066). In C, A549-sh-Ctr and A549-shNQO1 cells
were tested for clonal spheroid forming ability in the presence of 1%
methylcellulose, diluted 1:1 in 0.25% FBS/DMEM, as an alternative to 0.25%
FBS/DMEM medium. Data show significant loss in spheroid forming ability in
the A549-shNQO1 cell line in comparison to control, similar to what was
observed in experiments with low serum and DMEM only (** = p = 0.0084).
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Supplemental Figure 3. Inhibition of NQO1 activity results in loss of
spheroid generating capabilities. In A, parental A549 cells were tested for
their spheroid forming capabilities in both the presence and absence of the
NQO1 inhibitor, dicoumarol. Cells were plated for the spheroid assay and
treated with either vehicle control, or 50 µM dicoumarol and allowed to
incubate for 2 weeks. Following incubation, the number of spheroids formed
was enumerated. The inhibition of NQO1 leads to a significant decrease in
the sphere forming abilities of the A549 cell line. In B, the same experiment
was carried out using the H358 cell line, in which similar results were
obtained.
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Supplemental Figure 4. Spheroid cultured cells increase expression of stem cell
markers, and are lost upon differentiation. A549-shCtr and A549-shNQO1 cells were
pelleted prior to spheroid plating (shCtr and shNQO1), following two weeks of spheroid culture
(shCtr 1° Sphere and shNQO1 1° Sphere), and following one week of differentiation in 10%
FBS containing DMEM in an attached setting (shCtr 1° Sphere differentiated and shNQO1 1°
Sphere differentiated). Western blot analysis was performed in order to visualize the
expression of known stem cell markers SOX2, Shh, and Nanog. It was observed that there
was an increase in the stem cell markers as a result of spheroid culture in both the A549-shCtr
and A549-shNQO1 cell lines. The stem cell marker expression was subsequently decreased
following plating in differentiating conditions.
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Supplemental Figure 5. Spheroid culture conditions induce NQO1 expression
in A549-shNQO1 cells. Both A549-shCtr and A549-shNQO1 cells grown in spheroid
culture for 2 weeks were assayed for NQO1 expression. In A, Western blot analysis
demonstrating decreased expression of NQO1 in A549-shNQO1 spheres in
comparison to A549-shCtr spheres. In B, real-time qRT-PCR analysis demonstrating
a marked increase in NQO1 mRNA expression in spheroid cultured cells (A549shNQO1) in comparison to A549-shNQO1 cells grown in attached conditions (A549shNQO1 2D). (*** = p =0.0009) Additionally, it should be noted that the expression of
NQO1 mRNA in the A549-shNQO1 sphere cultured cells remains significantly
decreased in comparison to the A549-shCtr sphere cultured cells. (** = p =0.0018).
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Supplemental Figure 6. Spheroid formation is dependent on NQO1 expression. In A,
NQO1 expression was evaluated in the parental, shCtr, shNQO1, and 4C20 (second
clone) H358 cell lines. The 4C20 clone expresses a greater amount of NQO1 than that of
H358-shNQO1, and therefore was evaluated for its sphere forming abilities in B. In B, is
the quantification of the spheroid formation assay, including our 4C20 cell line. It can be
seen that with an increase in NQO1 expression there is an increase in spheroid formation,
suggesting that a critical level of NQO1 expression is necessary to support spheroid
formation.
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Chapter 4
Summary and Conclusions
Summary
The primary focus, for studies regarding cancer and NQO1, has been placed on
exploiting NQO1 as a tumor-specific drug target. The work to date in this research area
has provided a strong base of preclinical data, from which several clinical trials are now
being conducted. Despite the exhaustive interrogation into NQO1 as a tumor-specific
drug target, there has been little to no investigation into deciphering the antioxidant’s
role in the promotion and progression of cancer. The work presented in this dissertation
probed into the role NQO1 plays in (1) promoting tumorigenesis and (2) maintaining the
CSC population in NSCLC. Our results help to fill in the knowledge gap on the
supportive role NQO1 overexpression is playing in tumor initiation and progression.
In Chapter 2, we present our initial study investigating whether NQO1 plays a
supportive role in tumor initiation and progression in NSCLC. We began with
determining whether NQO1 is necessary to maintain a transformed phenotype. This
characteristic was assessed using a soft agar colony formation assay. This assay
demonstrates the ability of transformed cells to grow in a detached environment, and it
was observed that decreased expression of NQO1 severely impacted colony formation
(Chapter 2, Fig. 2A-D). These results indicate that, without increased expression of
NQO1, a phenotypic change occurs in which the cells have a reduced ability to
proliferate in anchorage-independent scenarios.
Next, the invasive capabilities of NSCLC cell lines were analyzed by performing the
spheroid invasion assay. When spheroids were implanted within a collagen I matrix, it
was observed that NQO1 was once again playing a positive role in promoting tumor cell
invasion. This characteristic was lost upon reduction of NQO1 (Chapter 2, Fig. 3A-D).
These results suggest that NQO1 has a supportive role in the promotion of tumor cell
invasion, and it can be postulated, although not shown in this study, that NQO1 may be
aiding in the formation of metastasis as invasion is a crucial step in the establishment of
metastatic growths (245).
NQO1 has been reported to function as a reactive oxygen species scavenger, and it
is well known that detachment from matrix can lead to increased reactive oxygen
species production(31, 230, 246). Given that we observed near complete loss of colony
formation in soft agar, we proceeded to evaluate the level of reactive oxygen species in
our cell lines. We determined that under detached conditions cells with their full
allotment of NQO1 had significantly lower levels of reactive oxygen species in
comparison to those in which NQO1 expression was reduced (Chapter 2, Fig. 4A,B). In
conjunction with these findings, we demonstrated that the detachment of NSCLC cells
from matrix also resulted in an increase in anoikis, or detachment-induced cell death
(Chapter 2, Fig. 4C,D). These results demonstrate the importance of NQO1 in the
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survival of NSCLC in detached environments, such as those encountered when
disseminated cancer cells become circulating tumor cells.
Next, in vivo tumorigenecity was evaluated by limited dilution assays in
immunocompromised mice. We observed that loss of NQO1 reduced tumor burden and
increased the overall survival of mice (Chapter 2, Fig. 5C-E). In an effort to better
determine how NQO1 is affecting the tumorigenic potential of NSCLC cells, we
evaluated the activity of known CSC marker ALDH. Surprisingly, we found significant
loss of ALDH activity following depletion of NQO1 (Chapter 2, Fig. 6). These results
demonstrate that NQO1 may be promoting tumor formation by enhancing the CSC
population. This is the first report, to our knowledge, that ties the expression of NQO1
to the activity of a known CSC marker in any cancer type.
The data presented in Chapter 2 is the first report in which NQO1 is evaluated for it’s
pro-tumorigenic role in the establishment of NSCLC. For the first time, NQO1 is
described as having an integral role in the formation, and progression of cancer. While
much has been done to target NQO1 due to its overexpression, our data provide the
first evidence that there may be alternative approaches to targeting tumor NQO1 levels,
mainly through the use of RNA interference (RNAi) technologies. RNAi technology has
been utilized previously, however only now has its clinical implications come to light.
Clinical application of this approach does not come easy however, as there are many
issues that exist with stability, delivery, and safety (247). Despite these current
roadblocks, continued research in this field furthers the application daily. This technique
could be a worthwhile option to explore, given the results we present herein. Reduction
of tumor NQO1 levels may work to inhibit further tumor growth, as well as the ability of
cells to survive during periods of detachment. Regardless of the known limitations of
this approach, the possibility of designing novel useful therapeutics will continue to be of
significant benefit to patients battling this grave disease.
Our results depicted in Chapter 2 drove us to further investigate the role that NQO1
plays in maintaining the CSC population within NSCLC. Observing the loss of ALDH
activity following depletion of NQO1 expression indicated that NQO1 might be altering
the CSC population in NSCLC. CSCs have been reported to be responsible for tumor
recurrence, resistance, and metastasis, and therefore further investigation into the role
NQO1 was playing to support this population was warranted (248). In order to
investigate this possibility, we utilized a number of well-established CSC assays, and
demonstrated that loss of NQO1 leads to a decrease in the prominence of the CSC
population.
Inquiry into NQO1 functioning to support the CSC phenotype began with evaluation
of in vitro tumor sphere formation. The spheroid assay evaluates the tumor initiating
capabilities of a cell population. Transformed cells are defined by the ability to survive
and proliferate in an anchorage-independent manner, as demonstrated by this assay
(249). In addition, the media utilized contains ultra-low levels of fetal bovine serum
(0.25%) that enhances the stem cell population by reducing the differentiation of stem
cells to their progenitors (57). Upon evaluation of the A549 and H358 NSCLC cell lines,
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we determined that reduction of NQO1 led to a significant decrease in the ability of
these populations to form spheroids. This result indicated that NQO1 was supporting
the growth and expansion of the NSCLC stem cell population (Chapter 3, Figure 2).
Spheroid formation demonstrated an enrichment in the CSC population in those lines
with their complete compliment of NQO1, however it is of paramount importance to
demonstrate self-renewal when attempting to demonstrate the presence of a CSC
population (250). To do so, primary spheroids where dissociated, both mechanically and
enzymatically, and plated into secondary spheroid assays, followed by tertiary plating.
In all scenarios, it was demonstrated that loss of NQO1 led to decreased spheroid
numbers, indicating that NQO1 is playing a supportive role in maintaining the CSC pool
within NSCLC (Chapter 3, Figure 4). Futhermore, we established NQO1 re-expression
in our A549-shNQO1 cell line, as well as the NQO1-null cell line H596, and
demonstrated a significant increase in the number of spheroids formed in comparison to
controls (Chapter 3, Figure 4C,D & Figure 5).
In order to quantify the number of tumor initiating CSC within our populations, we
employed the in vitro extreme limited dilution assay (ELDA). The ELDA assay functions
similarly to the spheroid assay, but utilizes limiting dilutions of cells, and software
(available at http://bioinf.wehi.edu.au/software/elda/), to calculate the number of CSCs.
The results from this assay demonstrated a greater than 10-fold enrichment in the A549
cell lines, as well as a doubling of the CSC population between the H358-shCtr and
H358-shNQO1 cell lines. In addition, there was a greater than 30-fold enrichment
between the A549-shCtr and H358-shCtr cell lines (Chapter 3, Table 1). This correlates
well with an increase in the sphere forming abilities of the A549 cell line versus that
which is seen in the H358 cell line (Chapter 3, Figure 2). The results of the ELDA
assay, spheroid formation, and NQO1 rescue experiments strongly back a supportive
role for NQO1 in the CSC population of NSCLC.
Finally, we evaluated the chemotherapeutic resistance of NQO1 knockdown cells
versus controls cultured as spheroids. CSCs are believed to be responsible for
therapeutic resistance (18, 44, 87), and it is of great importance to demonstrate this trait
when describing a CSC population. NSCLC spheroids were dissociated after two weeks
in culture and plated as single cells. This assay was carried out in this manner to evenly
treat all cells found within the spheroid. The spheroid model has been utilized as a drug
treatment model of micrometastasis, and functions to determine the diffusion limit of
drug across an avascular tumor (251). In addition, the CSC population has been
described to be centrally located within these spheroids and thus protected from drug
treatment (252). Single cell suspension was the only method by which to treat all cells of
the spheroid in an unbiased manner. A549 and H358-shCtr cells, treated for 24 hours
with increasing doses of cisplatin, displayed an increased survival over their NQO1
knockdown counterparts (Chapter 3, Fig. 6). These results demonstrated that NQO1
protected NSCLC cells from the deleterious effects of common, clinically utilized, anticancer therapeutics.
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Conclusions
Lung cancer continues to be the leading cause of cancer related deaths in the world
(2). This trend continues in spite of attempts to decrease lung cancer risk with
approaches such as smoking cessation. Declines in the percentage of the smoking
population in recent history
have yet to result in
significant decreases in lung
cancer incidence (Figure 1)
(253). These observations
indicate that there are other
contributors to the formation
of lung cancer besides
smoking, an example being
pollution (254). Regardless of
the extrinsic factors that are
influencing
lung
cancer
development, it is paramount Figure 1. Comparison of the percentage of the smoking population and
incidence rates. Over time, the percentage of the population of
to research and develop new NSCLC
individuals that smoke continues to drop in the United States (blue bars)
approaches to treating those however, the rate of lung cancer incidence remains steady (grey bars).
Smoking percentage data was collected from The National Health Interview
patients with the disease.
Survey,
1965-2014
available
at
http://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/index.ht

The modern age of anti- m. NSCLC incidence rate data was collected from the SEER database.
cancer therapy has gone
personal. The idea of personalized medicine is one in which many believe is the future
of cancer therapy (255, 256). Unveiling and understanding both new and old cancerpromoting pathways will reveal targets toward which to design new medications in an
effort to thwart pro-tumorigenic signaling. A major shortcoming with this approach
however, is the high rate of refractory disease (257). The eventual ineffectiveness of
targeted drugs requires that secondary and tertiary lines of therapy be developed in an
effort to prolong the positive response.
The CSC population is a unique population of cells that exist within each tumor
purportedly having unique abilities including therapeutic resistance, the ability to seed at
distant metastatic sites and to cause relapse of disease (32). The CSC populations
have become highly researched due to the belief that obliteration of this population will
lead to total eradication of tumors (258). In principal this idea is simple, but in practice it
is quite the challenge. Currently, there are few therapies that are targeted toward CSCs,
and often those therapies are ineffective or toxic to the patient (259, 260). An obvious
major roadblock to CSC targeted therapy is the utilization of markers that are also
present on somatic stem cells throughout the body (261). Eliminating the CSC
population has the very real potential to have an off-target effect on the somatic stem
cell population (262). From this perspective, it becomes clear that CSC targeted
therapies must target pathways, or markers, that are specific to cancer.
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NQO1 has repeatedly been demonstrated to be overexpressed in tumor in
comparison to normal tissues (116, 122). This has lead to the development of NQO1
targeted therapy that has progressed to clinic (263). This dissertation presents data that
fills in the void on NQO1’s role in NSCLC. We demonstrate that the up-regulation of
NQO1 observed in tumors promotes the tumorigenic characteristics and progression of
disease (Chapter 2). Additionally, we show a novel role for NQO1 in the maintenance
of the NSCLC CSC population (Chapter 3). These findings are important and impactful
for a number of reasons including 1) furthering the understanding of NQO1’s
mechanism of action in the promotion of NSCLC and 2) defining a novel stem cell
maintenance pathway. The results presented here provide the groundwork for future
studies that delve deeper into the workings of NQO1 as a tumor-promoting factor, and
argue that pharmaceutical approaches to reducing the tumor expression of NQO1 may
be a viable therapeutic strategy. Given that we demonstrate NQO1 to have a positive
role in supporting the CSC population, as well as tumor progression, the utilization of
therapies to reduce NQO1 expression, such as RNAi technology, could provide
clinicians with a two-headed approach; one that can stop cancer at the source, and
another that will reduce the malignant characteristics of the progenitor population.
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Chapter 5
Preliminary Data and Future Directions
Preliminary Data
Our investigation into the role of NQO1 in tumorigenesis and maintenance of the
CSC population has utilized gene manipulation via short hairpin RNA (shRNA)
technology. shRNA has provided investigators the ability to alter gene expression
through the specific targeting of messenger RNA encoding their gene of interest (264).
The formation of double stranded RNA through the binding of shRNA to the target
mRNA, leads to the destruction of both
the message and shRNA, thus
reducing the expression of protein
(265) (Figure 1A). The use of this tool
has unveiled numerous discoveries,
however the technology does not allow
for the complete elimination of protein
expression. In an effort to better
understand the role that NQO1 plays,
utilization of the CRISPR-Cas9 system
was incorporated into our ongoing
studies. CRISPR-Cas9 allows for
direct alteration of the genome that
results in the complete loss of protein
expression (266) (Figure 1A). For
these reasons we employed the
CRISPR-Cas9 system in our A549
NSCLC cell line in order to determine
the phenotypic effects of total NQO1
protein loss.
1. CRISPR-Cas9 genetic knockout of NQO1 in the
Studies
were
initiated
with Figure
A549 cell line. In A, model demonstrating shRNA targeting of
transfection of the lentiviral CRISPR- NQO1 leads to residual protein expression. Implementation of
technology will allow for complete resolution of
Cas9 system containing the small CRISPR-Cas9
NQO1 protein expression. In B, outline of small-guide RNA
guide RNA (sgRNA) toward NQO1 into (sgRNA) designed to target NQO1 utilizing the CRISPR-Cas9
PAM sequence highlighted in red. In C, Western blot
the A549 cell line (Figure 1B). system.
analysis of NQO1 expression in two CRISPR-Cas9 NQO1
Following selection with puromycin (2 knockout clones (A549 C-NQO1 1 and A549 C-NQO1 2). A549
as a positive control and H596 served as an NQO1-null
µg/ml), cells were plated in limited served
control. In D, complete loss of functional NQO1 activity was
dilution in order to acquire single cell demonstrated using the NQO1 activity kit (Abcam). ** = p=
clones
that
were
subsequently 0.0012
expanded. Once expanded, Western blot analysis was utilized to determine which, if
any, clones had lost NQO1 expression. We discovered two successful NQO1 knockout
clones (A549 C-NQO1 1 and A549 C-NQO1 2) as determined by Western blot, and
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subsequent sequencing (Figure 1C, Supplemental Figures 1-2). We then performed
an NQO1 activity test in order to confirm loss of protein activity (Figure 1D). It was
determined that there was no significant difference in NQO1 activity between the
parental A549 cell line (A549) and the CRISPR-Cas9 control (A549 C-Ctr), however
there was complete loss of NQO1 activity in the A549 C-NQO1 1 and A549 C-NQO1 2
cell lines. Absence of activity was confirmed by comparison to the NQO1*2 cell line
H596, which is known to lack functional NQO1. These results demonstrate that
utilization of the CRISPR-Cas9 system resulted in the creation of A549 NQO1-null cell
lines, the first of their kind to our knowledge.
We next investigated the effect of
complete NQO1 loss in a number of
assays that we have previously
employed. These included spheroid
formation, soft agar colony formation,
and drug resistance. Surprisingly there
was no significant difference in the
number of spheroids (Figure 2A & B)
or colonies formed (Figure 2C & D).
Additionally, no alterations in resistance
to the platinum based chemotherapy
cisplatin were noted between our A549
C-Ctr and C-NQO1 knockout cell lines
(Figure 2E). These results were
surprising given that our results with
shRNA-NQO1 knockdown in A549 cells
led to a significant decrease in all of
these assays. In order to account for
this difference, we compared the
differences between the two methods.
We concluded one method (shRNA)
directly targets mRNA, whereas the
CRISPR-Cas9 approach directly edits
the genome and may result in the
production of a non-translatable mRNA.
This
understanding
led
us
to
hypothesize that it is not NQO1 protein,
but the NQO1 mRNA that is responsible
for
maintaining
the
observed
phenotype.

Figure 2. NQO1 knockout has no effect on spheroid
formation, soft agar colony formation, or cisplatin
resistance. In A, A549 NQO1 knockout clones (A549 C-NQO1
1 and A549 C-NQO1 2) were placed into a spheroid assay, and
after two weeks the number of spheres were quantified. In B,
representative images of spheroids formed in A. In C, Knockout
clones were also placed into soft agar colony formation, where
there was no significant difference in the number of colonies
formed between the NQO1 knockouts and control. In D,
representative images of soft agar colony formation. In E, NQO1
knockout clones were treated with 0, 2.5, 5, and 10 µM cisplatin
for 24 hours and evaluated for viability utilizing the Cell-titer Glo
assay. The results demonstrated no significant difference in
survival.
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We
first
evaluated
the
expression
of
Figure 3. CRISPR-Cas9 knockout
NQO1 mRNA in
clones produce NQO1 mRNA, and
its reduction inhibits spheroid
our A549 Cformation. In A, NQO1 knockout
NQO1 cell lines
clones were evaluated for NQO1
mRNA expression via real-time
(C-NQO1 1 and
qRT-PCR, and demonstrate no
C-NQO1
2)
difference in transcript levels in
comparison to controls. In B,
versus the A549
transient knockdown of NQO1
C-Ctr.
Results
mRNA was successfully achieved
by using siRNA directed at NQO1,
demonstrated
and validated using real-time qRTthat there was
PCR. In C, A549 C-NQO1 1 siCtr
and siNQO1 cell lines were placed
no alteration in
into the spheroid assay, and
the expression
quantified. A statistically significant
difference in spheroid formation was
of NQO1 mRNA
noted (* = p = 0.016). In D, the area
in the A549 Cof the siCtr and siNQO1 spheroids
was evaluated and a significant
NQO1
in
reduction in sphere area was
comparison
to
observed (* = p = 0.0161). In E,
representative images of spheroids
A549
C-Ctr.
formed in both A549 C-NQO1 1
(Figure 3A) In
siCtr and siNQO1 cell lines.
an
effort
to
reduce
the
expression
of
NQO1 mRNA in
the A549 CNQO1 1 cell line, we transiently knocked down the mRNA levels using siRNA directed
toward NQO1. Significant reduction in the expression of NQO1 mRNA was achieved in
both the A549 C-Ctr and C-NQO1 1 cell lines, as determined by real-time qRT-PCR
(Figure 3B). We next evaluated the sphere forming ability of the cells treated with
siRNA toward NQO1 (A549 C-NQO1 1 siNQO1) versus the scrambled control (A549 CNQO1 siCtr). Results demonstrate a significant decrease in the sphere forming ability,
of those cells treated with siRNA toward NQO1 (Figure 3C). Additionally, when
measuring the size of spheres formed, a significant decrease in sphere area was
observed in the siRNA treated cells versus those treated with control.
These results are the initial demonstrations of a novel role for NQO1 mRNA, the
regulation of the CSC phenotype in NSCLC. While these results are preliminary, they
provide enough support to postulate a mechanism by which the NQO1 mRNA is playing
a signaling role in NSCLC. We hypothesize that NQO1 mRNA is acting as a micro-RNA
(miR) sponge for a possible number of known CSC associated miRs, including the Let-7
family, miR-34a, and miR-143 (267-269). (Figure 4A) Reduction of the listed miRs has
been demonstrated previously to result in an increase in the CSC phenotype that would
coincide with our observation that reduction of NQO1 mRNA results in decreased
prominence of the CSC phenotype, possibly thorough the liberation of the listed miRs
(268, 270, 271). (Figure 4B) In addition, the miRs listed have been predicted to bind to
NQO1 mRNA according to the prediction software available at www.targetscan.org.
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Future studies will be necessary in
order to confirm the relationship of
NQO1 mRNA with that of the listed,
and possibly greater numbers of miRs.
These results implicate the NQO1
message as having a crucial role in
the maintenance of the CSC and
transformed phenotype of NSCLC. In
addition these results support our
previous proclamation that therapies
focused on reduction of NQO1 may
serve useful in clinic. The application
of RNAi technology to reduce
expression in patients may provide
increased
survival
and
better
prognosis through the lessening of the
pro-tumor effects demonstrated by the
expression of NQO1.

Figure 4. NQO1 mRNA may function as a miR sponge and
promote the CSC phenotype. In A, schematic of possible NQO1
mRNA mechanism in regulating the CSC phenotype. Classically,
NQO1 mRNA is transcribed and then translated into a functional
protein. Preliminary data suggests that NQO1 protein expression
and activity is not responsible for its promotion of the CSC
phenotype, as complete loss does not abolish the CSC traits that
are apparent when NQO1 protein is present. Instead, we propose
that NQO1 mRNA is playing a functional role by acting as a miR
sponge to inhibit the actions of miRs known to be involved in the
CSC phenotype, such as the let-7 family, miR-34a, and mIR-143 .
In B, a model showing demonstrating NQO1 mRNA expression
leads to a decrease in miRs that result in the emergence of the
CSC in NSCLC.
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Supplemental Figures

Supplemental Figure 1. Sequencing validation of C-NQO1 1 CRISPR-Cas9
mediated knockout of NQO1. In A, BLAST sequence alignment of C-NQO1 1 (subjct)
demonstrating a 26 nucleotide deletion, in comparison to the control (query), in one
NQO1 allele. In B, sequencing histogram illustrating the 26 nucleotide deletion seen in
A. In C, BLAST sequence alignment of C-NQO1 1 (subjct) demonstrating a 9
nucleotide deletion, in comparison to the control (query), in the second NQO1 allele. In
D, sequencing histogram illustrating the 9 nucleotide deletion seen in C.
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.

Supplemental Figure 2. Sequencing validation of C-NQO1 2 CRISPR-Cas9 mediated
knockout of NQO1. In A, BLAST sequence alignment of C-NQO1 2 (subjct)
demonstrating a 10 nucleotide deletion, in comparison to the control (query), in one NQO1
allele. In B, sequencing histogram illustrating the 10 nucleotide deletion seen in A. In C,
BLAST sequence alignment of C-NQO1 1 (subjct) demonstrating a 17 nucleotide deletion,
in comparison to the control (query), in the second NQO1 allele. In D, sequencing
histogram illustrating the 17 nucleotide deletion seen in C.
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Materials and Methods
Cell Culture
A549, A549 C-NQO1 1, A549 C-NQO1 2, and H596 cell lines were grown in
Dulbecco’s Modified Eagles Media (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% L-glutamine. Cell lines were cultured at 37° C with 20% oxygen and 5%
carbon dioxide prior to spheroid culture. Cells were passaged weekly and supplemented
with fresh media.
Western blotting
Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room
temperature, and then incubated overnight with β-actin (1:5000, Santa Cruz
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa
Cruz Biotechnology), SOX2 (1:1000, Cell Signaling), Shh (1:1000, Cell Signaling), Oct-4
(1:1000, Cell Signaling), and Nanog (1:1000, Cell Signaling). Pierce ECL western
blotting substrate (Thermo Scientific) was used to visual bands on Hyblot-CL
autoradiography film (Denville Scientific)
NQO1 Activity Assay
NQO1 enzyme activity was performed as previously described. (144) Briefly, 2x107
cells of each cell line were collected. Pellets were solubilized in extraction buffer for 20
min, after which they were centrifuged at 18,000 x g for 20 min at 4° C. Supernatants
were collected into eppendorf tubes at stored at -80° C. Samples were then run
according to the manufacturers protocol for the NQO1 activity assay kit from Abcam.
Results were read at an absorbance of 440 nm every 20 seconds for 5 minutes utilizing
the Synergy-H1 Hybrid microplate reader. Plates were shaken both before and after
each reading.
CRISPR-Cas9 knockout
CRISPR targeting sequences toward NQO1 were generated using the available
software from crispr.mit.edu. The sgRNA guide sequences that were designed were:
NQO1:
5’-CACCGCAGAAGAGCACTGATCGTAC-3’
and
5’AAACGTACGATCAGTGCTCTTCTGC-3’. The lentiCRISPRv2 backbone was digested
and dephosphorylated using the BsmBI restriction enzyme and gel purified using the
QIAEX II Gel Extraction Kit. (Qiagen) The sgRNA guides were then annealed and then
ligated with the purified plasmid. Stbl3 bacteria were then transformed with the plasmid
via heat shock and plated on carbenicillin containing agar. Colonies were selected and
a mini-prep (Qiagen) was performed. Samples were then cut and run on an agarose gel
in order to determine sequence insertion. Promising clones were then sequenced.
Clones containing the insert were then maxi-prepped and collected plasmid was used to
transfect Phoenix 293T cells. Media containing the lentiviral particles was then collected
at 24, 48, and 72 hours.
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In order to generate NQO1 knockout cell lines, the lentivirus-containing media was
added to cells at a 1:1 ratio with fresh 10% FBS DMEM. The virus was allowed to
incubate with the cells for 24 hours after which they began to undergo selection.
Selection was carried out using 2 ug/ml puromycin over a minimum period of two
weeks. Following recovery from selection, the cell lines were placed into limited dilution
and single cell clones were chosen for expansion. Selected clones were then evaluated
via Western blot for NQO1 expression and subsequently sequenced to confirm NQO1
disruption.
Spheroid Formation
Low attachment cell culture plates (Corning) were produced by coating the plates
with a 0.2% poly-hema/95% ethanol solution. Plates were incubated at 60° C overnight
and allowed to dry. The process was then repeated a second time. Plates were washed
twice with milli-Q water immediately prior to use.
Cells were trypsinized and treated with trypsin neutralizing solution (1:1 ratio) prior to
being counted using a hemacytometer. 10,000 were then plated in the low attachment
100 mm plates in 0.25% FBS DMEM supplemented with 1% L-glutamine. Cells were
allowed to form spheroids over 14 days, at which time they were collected, trypsinized
into single cell suspensions, and utilized for future assays
. Drug Treatment Studies
Spheroids were collected after 14 days and trypsinized into single cell suspension.
Cells were counted and suspended in DMEM media supplemented with 0.25% FBS and
1% L-glutamine at a concentration of 10,000 cells/ml. 200 ul of cell suspension was
then added to each well. Cells were allowed to attach overnight, and the following day
were treated with 0, 2.5, 5, and 10 uM cisplatin dissolved in DMSO. Stock
concentrations of 2.5, 5, and 10 mM cisplatin were diluted 1:1000 in 0.25% FBS DMEM
supplemented with 1% L-glutamine and incubated on cells overnight. Each dose was
performed in 8 replicates for each dose tested. Twenty-four hours after initial treatment,
cell viability was assessed using Cell-Titer Glo (Promega), according to the
manufacturer’s protocol utilizing the Synergy-H1 Hybrid Reader.
Transient and stable NQO1 mRNA knockdown assays
The human shRNA-NQO1 retroviral vector was purchased from Open Biosystems.
The stable shRNA knockdown cell line (A549 C-NQO1 shNQO1) was generated by
infecting A549 C-NQO1 cells with polybrene-supplemented medium obtained from
Phoenix packaging cells transfected with the human retrovirus vector targeting NQO1
as described previously (168). Medium was changed 24 hours after transfection. After
48 hours shNQO1 containing cells were isolated by limited dilution in media containing
puromycin (2 µg/mL) and screened for NQO1 mRNA expression levels by real-time
qRT-PCR. For transient NQO1 knockdown, siRNA-NQO1 or scramble control siRNA
(Santa Cruz Biotechnology) was transiently transfected into HCC1171 cell lines
(Lipofectamine 2000, Life technologies) using the Life technologies protocol. Cells were
harvested after 48 hours and analyzed for NQO1 mRNA expression.
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Anchorage independent growth assays
A 1.5% SeaPlaque Agarose (SPA) mixture was made by slowly adding SPA to PBS
and autoclaving. 0.5% SPA was created by diluting the 1.5% stock SPA 1:3 with culture
media. 1 mL of the 0.5% SPA mixture was added to each well of a 6 well plate to create
a bottom layer and allowed to solidify at room temperature for 15-20 minutes. Cells
were counted and suspended at 750 cells/mL in a separate 0.5% SPA mixture. 2 mL
were added to each well on top of the bottom layer and allowed to solidify for 30-45
minutes at room temperature to create a cell layer. A 0.3% SPA mixture was created by
diluting the 1.5 % stock SPA 1:5 with culture media. 1 mL of the 0.3% SPA mixture was
added to each cell layer and allowed to solidify for 20-30 minutes at room temperature
to create a top layer. 250-500 µL of culture media was added onto the top layer to
prevent from drying out. Plates were wrapped in parafilm and placed at 37°C. 250-500
µL of new culture media was added every week. Plates were imaged after 3 weeks
using and Epson V700 photo scanner. The enumeration of colonies present in each
dish was quantified using imageJ software.
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Future Directions
The expression levels of NQO1 have long been shown to be elevated in a number of
malignancies, in comparison to their normal controls (116). This increased expression
has led to the targeting of NQO1 through the utilization of NQO1 bioactivateable drugs
(170, 174). While the bulk of research has focused on improving NQO1 targeted
therapies, there has been very little done to determine the functional role of NQO1 in
the cancer cell. The work presented here aimed to fill in the void of NQO1’s function in
malignancies by evaluating a number of tumorigenic properties. We demonstrated that
NQO1 was vital for anchorage independent growth, anoikis resistance, invasion, ROS
regulation, tumor growth, and ALDH activity. The alteration of a known CSC marker’s
activity drove us to investigate NQO1’s role as a possible CSC marker.
Our investigations into NQO1 as a CSC marker led to some quite interesting results.
We were able to demonstrate that loss of NQO1 led to a decrease in spheroid
formation, in both primary and serial spheroid cultures. In addition, we show that
spheroid cultured A549-shCtr cells have increased drug resistance and proliferation.
These results strongly support NQO1 as a major supporter of the CSC phenotype.
Additionally we argue that reduction of NQO1 in patient tumors may be a useful strategy
in eliminating the CSC population.
Finally, we investigated the effect of total loss of NQO1 through the implementation
of the CRISP-Cas9 system. To our surprise, complete loss of NQO1 did not affect
sphere formation, soft agar colony formation or the drug resistance that was observed in
our shRNA-NQO1 knockdown studies (Chapter 2). In an effort to determine if NQO1
mRNA was involved, a transient knock down of NQO1 mRNA by utilization of RNAi
technology was implemented. The transient reduction of NQO1 mRNA led to a
decrease in spheroid formation indicating NQO1 mRNA may be involved in maintaining
the transformed phenotype. These data also present the possibility that NQO1 mRNA is
a contributing factor in our previously published work (Chapter 2).
The future focus of this project should center on NQO1 mRNA and the mechanism
by which it is affecting both the transformed phenotype, and the CSC population. It has
been shown previously that a number of miRs are capable of altering the CSC
population. Additionally, the mechanism by which mRNA functions as a miR sponge has
been well documented (272-274). Given that reduction of these purported miR leads to
an increase in the CSC phenotype, the hypothesis that NQO1 mRNA is acting as a miR
sponge would align with these observations.
Future efforts will need to be made in order to determine the miRs that are capable
of binding to NQO1 mRNA, and whether or not NQO1 mRNA can function as a suitable
mRNA sponge. Some techniques that may be utilized in this effort include RISC
complex immunoprecipitateion, HITS-CLIP, PAR-CLIP, and labeling of miRs or mRNA
in order to perform immunoprecipitation (275-277). Given the massive effort being put
forth into identifying and validating miRs, validating those that associate with NQO1
mRNA will provide future work with a solid foothold on which to build an understanding
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of the mechanism of NQO1 mRNA regulation of tumorigenesis, as well as the cancer
stem cell population. Validation of the role of NQO1 mRNA in tumorigenesis can
ultimately lead to development of clinically relevant drugs that target this mRNA, the
miRs it regulates, or downstream pathways that may be driving these tumors.
Finally, investigation of NQO1 mRNA expression and its inhibition in tumors that
have an NQO1 polymorphism may explain why those tumors lacking functional NQO1
protein may still be capable of forming tumors. To our knowledge there are no
exhaustive investigations into the expression of NQO1 mRNA in polymorphic tumors
tumors, however moderate mRNA expression has been reported in polymorphic cell
lines (134, 278).It would be interesting to evaluate the mRNA expression in polymorphic
cells and demonstrate that reduction of NQO1 mRNA results in an attenuated
tumorigenecity. In closing, there is an unknown amount of information that has yet to be
revealed pertaining to NQO1. Previous work on NQO1 mainly focused on utilizing
bioactivateable drugs to specifically target NQO1 over-expressing tumor cells. The
future of NQO1 research should focus more on NQO1’s pro-tumorigenic role, as protein
over-expression and increased activity does not appear to be the only means by which
NQO1 promotes tumorigenesis.
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